KR20200107990A - 신경 생존 인자를 포함하는 컨스트럭트 및 이의 용도 - Google Patents
신경 생존 인자를 포함하는 컨스트럭트 및 이의 용도 Download PDFInfo
- Publication number
- KR20200107990A KR20200107990A KR1020207021370A KR20207021370A KR20200107990A KR 20200107990 A KR20200107990 A KR 20200107990A KR 1020207021370 A KR1020207021370 A KR 1020207021370A KR 20207021370 A KR20207021370 A KR 20207021370A KR 20200107990 A KR20200107990 A KR 20200107990A
- Authority
- KR
- South Korea
- Prior art keywords
- nucleic acid
- adeno
- rdcvf
- aav
- seq
- Prior art date
Links
- 230000004083 survival effect Effects 0.000 title abstract description 14
- 210000005036 nerve Anatomy 0.000 title description 3
- 230000002207 retinal effect Effects 0.000 claims abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 20
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 19
- 230000014509 gene expression Effects 0.000 claims description 67
- 101000597433 Mus musculus Nucleoredoxin-like protein 1 Proteins 0.000 claims description 63
- 150000007523 nucleic acids Chemical class 0.000 claims description 55
- 108020004707 nucleic acids Proteins 0.000 claims description 49
- 102000039446 nucleic acids Human genes 0.000 claims description 49
- 239000002773 nucleotide Substances 0.000 claims description 30
- 125000003729 nucleotide group Chemical group 0.000 claims description 30
- 239000013598 vector Substances 0.000 claims description 30
- 241000702423 Adeno-associated virus - 2 Species 0.000 claims description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 101000597428 Homo sapiens Nucleoredoxin-like protein 1 Proteins 0.000 description 77
- 102100035399 Nucleoredoxin-like protein 1 Human genes 0.000 description 64
- 108020004414 DNA Proteins 0.000 description 32
- 241000282414 Homo sapiens Species 0.000 description 25
- 239000002299 complementary DNA Substances 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 19
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 16
- 102000001708 Protein Isoforms Human genes 0.000 description 15
- 108010029485 Protein Isoforms Proteins 0.000 description 15
- 210000004185 liver Anatomy 0.000 description 14
- 239000013607 AAV vector Substances 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 101000825217 Homo sapiens Meiotic recombination protein SPO11 Proteins 0.000 description 10
- 102100022253 Meiotic recombination protein SPO11 Human genes 0.000 description 10
- 201000007737 Retinal degeneration Diseases 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 238000004806 packaging method and process Methods 0.000 description 8
- 230000004258 retinal degeneration Effects 0.000 description 8
- 241000701959 Escherichia virus Lambda Species 0.000 description 7
- 210000000234 capsid Anatomy 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000005538 encapsulation Methods 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 108091008695 photoreceptors Proteins 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108020004705 Codon Proteins 0.000 description 6
- 102000002933 Thioredoxin Human genes 0.000 description 6
- 238000001415 gene therapy Methods 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 210000001525 retina Anatomy 0.000 description 6
- 108060008226 thioredoxin Proteins 0.000 description 6
- 102100020714 Fragile X mental retardation 1 neighbor protein Human genes 0.000 description 5
- 101000932499 Homo sapiens Fragile X mental retardation 1 neighbor protein Proteins 0.000 description 5
- 241000282577 Pan troglodytes Species 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 102000057445 human NXNL1 Human genes 0.000 description 5
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 4
- KFKWRHQBZQICHA-STQMWFEESA-N L-leucyl-L-phenylalanine Natural products CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 KFKWRHQBZQICHA-STQMWFEESA-N 0.000 description 4
- 201000003533 Leber congenital amaurosis Diseases 0.000 description 4
- 108020004682 Single-Stranded DNA Proteins 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000007850 degeneration Effects 0.000 description 4
- 230000004438 eyesight Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 108010044056 leucyl-phenylalanine Proteins 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 238000005215 recombination Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 229940094937 thioredoxin Drugs 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 241000702421 Dependoparvovirus Species 0.000 description 3
- 208000032400 Retinal pigmentation Diseases 0.000 description 3
- 238000013103 analytical ultracentrifugation Methods 0.000 description 3
- 238000003936 denaturing gel electrophoresis Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 102000054766 genetic haplotypes Human genes 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 108091070501 miRNA Proteins 0.000 description 3
- 239000002679 microRNA Substances 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 description 3
- 210000000880 retinal rod photoreceptor cell Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 241001164825 Adeno-associated virus - 8 Species 0.000 description 2
- BLGHHPHXVJWCNK-GUBZILKMSA-N Ala-Gln-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O BLGHHPHXVJWCNK-GUBZILKMSA-N 0.000 description 2
- IHMCQESUJVZTKW-UBHSHLNASA-N Ala-Phe-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](C)N)CC1=CC=CC=C1 IHMCQESUJVZTKW-UBHSHLNASA-N 0.000 description 2
- OTZMRMHZCMZOJZ-SRVKXCTJSA-N Arg-Leu-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O OTZMRMHZCMZOJZ-SRVKXCTJSA-N 0.000 description 2
- RTDZQOFEGPWSJD-AVGNSLFASA-N Arg-Leu-Val Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O RTDZQOFEGPWSJD-AVGNSLFASA-N 0.000 description 2
- KXFCBAHYSLJCCY-ZLUOBGJFSA-N Asn-Asn-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O KXFCBAHYSLJCCY-ZLUOBGJFSA-N 0.000 description 2
- RRUWMFBLFLUZSI-LPEHRKFASA-N Asp-Met-Pro Chemical compound CSCC[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)O)N RRUWMFBLFLUZSI-LPEHRKFASA-N 0.000 description 2
- YIDFBWRHIYOYAA-LKXGYXEUSA-N Asp-Ser-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O YIDFBWRHIYOYAA-LKXGYXEUSA-N 0.000 description 2
- 102100021277 Beta-secretase 2 Human genes 0.000 description 2
- 101710150190 Beta-secretase 2 Proteins 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- 108090000565 Capsid Proteins Proteins 0.000 description 2
- 102100023321 Ceruloplasmin Human genes 0.000 description 2
- IKDOHQHEFPPGJG-FXQIFTODSA-N Gln-Asp-Glu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O IKDOHQHEFPPGJG-FXQIFTODSA-N 0.000 description 2
- XEYMBRRKIFYQMF-GUBZILKMSA-N Gln-Asp-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O XEYMBRRKIFYQMF-GUBZILKMSA-N 0.000 description 2
- LKDIBBOKUAASNP-FXQIFTODSA-N Glu-Ala-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O LKDIBBOKUAASNP-FXQIFTODSA-N 0.000 description 2
- HNVFSTLPVJWIDV-CIUDSAMLSA-N Glu-Glu-Gln Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O HNVFSTLPVJWIDV-CIUDSAMLSA-N 0.000 description 2
- GQGAFTPXAPKSCF-WHFBIAKZSA-N Gly-Ala-Cys Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@@H](CS)C(=O)O GQGAFTPXAPKSCF-WHFBIAKZSA-N 0.000 description 2
- OCQUNKSFDYDXBG-QXEWZRGKSA-N Gly-Arg-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCN=C(N)N OCQUNKSFDYDXBG-QXEWZRGKSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000597425 Homo sapiens Nuclear RNA export factor 2 Proteins 0.000 description 2
- 101000729271 Homo sapiens Retinoid isomerohydrolase Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- JUWJEAPUNARGCF-DCAQKATOSA-N Leu-Arg-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O JUWJEAPUNARGCF-DCAQKATOSA-N 0.000 description 2
- CLVUXCBGKUECIT-HJGDQZAQSA-N Leu-Asp-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CLVUXCBGKUECIT-HJGDQZAQSA-N 0.000 description 2
- AVEGDIAXTDVBJS-XUXIUFHCSA-N Leu-Ile-Arg Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O AVEGDIAXTDVBJS-XUXIUFHCSA-N 0.000 description 2
- UBZGNBKMIJHOHL-BZSNNMDCSA-N Leu-Leu-Phe Chemical compound CC(C)C[C@H]([NH3+])C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C([O-])=O)CC1=CC=CC=C1 UBZGNBKMIJHOHL-BZSNNMDCSA-N 0.000 description 2
- PTRKPHUGYULXPU-KKUMJFAQSA-N Leu-Phe-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(O)=O PTRKPHUGYULXPU-KKUMJFAQSA-N 0.000 description 2
- ICYRCNICGBJLGM-HJGDQZAQSA-N Leu-Thr-Asp Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(O)=O ICYRCNICGBJLGM-HJGDQZAQSA-N 0.000 description 2
- MSFITIBEMPWCBD-ULQDDVLXSA-N Leu-Val-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 MSFITIBEMPWCBD-ULQDDVLXSA-N 0.000 description 2
- QIJVAFLRMVBHMU-KKUMJFAQSA-N Lys-Asp-Phe Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O QIJVAFLRMVBHMU-KKUMJFAQSA-N 0.000 description 2
- KXYLFJIQDIMURW-IHPCNDPISA-N Lys-Trp-Leu Chemical compound C1=CC=C2C(C[C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](N)CCCCN)=CNC2=C1 KXYLFJIQDIMURW-IHPCNDPISA-N 0.000 description 2
- WXHHTBVYQOSYSL-FXQIFTODSA-N Met-Ala-Ser Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O WXHHTBVYQOSYSL-FXQIFTODSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 2
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 2
- 102100035403 Nuclear RNA export factor 2 Human genes 0.000 description 2
- 102100036205 Nucleoredoxin-like protein 2 Human genes 0.000 description 2
- 101710106007 Nucleoredoxin-like protein 2 Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- MPFGIYLYWUCSJG-AVGNSLFASA-N Phe-Glu-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 MPFGIYLYWUCSJG-AVGNSLFASA-N 0.000 description 2
- JJHVFCUWLSKADD-ONGXEEELSA-N Phe-Gly-Ala Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H](C)C(O)=O JJHVFCUWLSKADD-ONGXEEELSA-N 0.000 description 2
- LRBSWBVUCLLRLU-BZSNNMDCSA-N Phe-Leu-Lys Chemical compound CC(C)C[C@H](NC(=O)[C@@H](N)Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(O)=O LRBSWBVUCLLRLU-BZSNNMDCSA-N 0.000 description 2
- OSBADCBXAMSPQD-YESZJQIVSA-N Phe-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)N OSBADCBXAMSPQD-YESZJQIVSA-N 0.000 description 2
- ZOGICTVLQDWPER-UFYCRDLUSA-N Phe-Tyr-Val Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(O)=O ZOGICTVLQDWPER-UFYCRDLUSA-N 0.000 description 2
- GLUYKHMBGKQBHE-JYJNAYRXSA-N Phe-Val-Arg Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 GLUYKHMBGKQBHE-JYJNAYRXSA-N 0.000 description 2
- SNIPWBQKOPCJRG-CIUDSAMLSA-N Pro-Gln-Cys Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CS)C(=O)O SNIPWBQKOPCJRG-CIUDSAMLSA-N 0.000 description 2
- VZKBJNBZMZHKRC-XUXIUFHCSA-N Pro-Ile-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O VZKBJNBZMZHKRC-XUXIUFHCSA-N 0.000 description 2
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 2
- 208000014769 Usher Syndromes Diseases 0.000 description 2
- AJNUKMZFHXUBMK-GUBZILKMSA-N Val-Ser-Arg Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N AJNUKMZFHXUBMK-GUBZILKMSA-N 0.000 description 2
- RYHUIHUOYRNNIE-NRPADANISA-N Val-Ser-Gln Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N RYHUIHUOYRNNIE-NRPADANISA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 2
- 108010038633 aspartylglutamate Proteins 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000003793 centrosome Anatomy 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 108010060199 cysteinylproline Proteins 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 108010034529 leucyl-lysine Proteins 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 108010016686 methionyl-alanyl-serine Proteins 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001566 pro-viral effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 210000000964 retinal cone photoreceptor cell Anatomy 0.000 description 2
- 150000004492 retinoid derivatives Chemical class 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 230000004393 visual impairment Effects 0.000 description 2
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- WDIYWDJLXOCGRW-ACZMJKKPSA-N Ala-Asp-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O WDIYWDJLXOCGRW-ACZMJKKPSA-N 0.000 description 1
- BIOCIVSVEDFKDJ-GUBZILKMSA-N Arg-Arg-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O BIOCIVSVEDFKDJ-GUBZILKMSA-N 0.000 description 1
- KWTVWJPNHAOREN-IHRRRGAJSA-N Arg-Asn-Phe Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O KWTVWJPNHAOREN-IHRRRGAJSA-N 0.000 description 1
- KMSHNDWHPWXPEC-BQBZGAKWSA-N Arg-Asp-Gly Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O KMSHNDWHPWXPEC-BQBZGAKWSA-N 0.000 description 1
- MFAMTAVAFBPXDC-LPEHRKFASA-N Arg-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O MFAMTAVAFBPXDC-LPEHRKFASA-N 0.000 description 1
- LLZXKVAAEWBUPB-KKUMJFAQSA-N Arg-Gln-Phe Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O LLZXKVAAEWBUPB-KKUMJFAQSA-N 0.000 description 1
- CYXCAHZVPFREJD-LURJTMIESA-N Arg-Gly-Gly Chemical compound NC(=N)NCCC[C@H](N)C(=O)NCC(=O)NCC(O)=O CYXCAHZVPFREJD-LURJTMIESA-N 0.000 description 1
- RKQRHMKFNBYOTN-IHRRRGAJSA-N Arg-His-Lys Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N RKQRHMKFNBYOTN-IHRRRGAJSA-N 0.000 description 1
- NMRHDSAOIURTNT-RWMBFGLXSA-N Arg-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N NMRHDSAOIURTNT-RWMBFGLXSA-N 0.000 description 1
- TZQWZQSMHDVLQL-QEJZJMRPSA-N Asn-Trp-Gln Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N TZQWZQSMHDVLQL-QEJZJMRPSA-N 0.000 description 1
- WBDWQKRLTVCDSY-WHFBIAKZSA-N Asp-Gly-Asp Chemical compound OC(=O)C[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O WBDWQKRLTVCDSY-WHFBIAKZSA-N 0.000 description 1
- 208000037663 Best vitelliform macular dystrophy Diseases 0.000 description 1
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
- ABLJDBFJPUWQQB-DCAQKATOSA-N Cys-Leu-Arg Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CS)N ABLJDBFJPUWQQB-DCAQKATOSA-N 0.000 description 1
- UIKLEGZPIOXFHJ-DLOVCJGASA-N Cys-Phe-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(O)=O UIKLEGZPIOXFHJ-DLOVCJGASA-N 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- ZBKUIQNCRIYVGH-SDDRHHMPSA-N Gln-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)N)N ZBKUIQNCRIYVGH-SDDRHHMPSA-N 0.000 description 1
- RUFHOVYUYSNDNY-ACZMJKKPSA-N Glu-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O RUFHOVYUYSNDNY-ACZMJKKPSA-N 0.000 description 1
- VAIWPXWHWAPYDF-FXQIFTODSA-N Glu-Asp-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O VAIWPXWHWAPYDF-FXQIFTODSA-N 0.000 description 1
- JVSBYEDSSRZQGV-GUBZILKMSA-N Glu-Asp-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CCC(O)=O JVSBYEDSSRZQGV-GUBZILKMSA-N 0.000 description 1
- SJPMNHCEWPTRBR-BQBZGAKWSA-N Glu-Glu-Gly Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O SJPMNHCEWPTRBR-BQBZGAKWSA-N 0.000 description 1
- OQXDUSZKISQQSS-GUBZILKMSA-N Glu-Lys-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O OQXDUSZKISQQSS-GUBZILKMSA-N 0.000 description 1
- TWYFJOHWGCCRIR-DCAQKATOSA-N Glu-Pro-Arg Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O TWYFJOHWGCCRIR-DCAQKATOSA-N 0.000 description 1
- VIPDPMHGICREIS-GVXVVHGQSA-N Glu-Val-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O VIPDPMHGICREIS-GVXVVHGQSA-N 0.000 description 1
- XPJBQTCXPJNIFE-ZETCQYMHSA-N Gly-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)CN XPJBQTCXPJNIFE-ZETCQYMHSA-N 0.000 description 1
- FFJQHWKSGAWSTJ-BFHQHQDPSA-N Gly-Thr-Ala Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O FFJQHWKSGAWSTJ-BFHQHQDPSA-N 0.000 description 1
- 208000007698 Gyrate Atrophy Diseases 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- BSWLQVGEVFYGIM-ZPFDUUQYSA-N Ile-Gln-Arg Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N BSWLQVGEVFYGIM-ZPFDUUQYSA-N 0.000 description 1
- LFSQWRSVPNKJGP-WDCWCFNPSA-N Leu-Thr-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(O)=O LFSQWRSVPNKJGP-WDCWCFNPSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 210000005156 Müller Glia Anatomy 0.000 description 1
- 108010002311 N-glycylglutamic acid Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 102000010175 Opsin Human genes 0.000 description 1
- 108050001704 Opsin Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 101100082606 Plasmodium falciparum (isolate 3D7) PDEbeta gene Proteins 0.000 description 1
- 108091008109 Pseudogenes Proteins 0.000 description 1
- 102000057361 Pseudogenes Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000005587 Refsum Disease Diseases 0.000 description 1
- 208000032430 Retinal dystrophy Diseases 0.000 description 1
- 102100031176 Retinoid isomerohydrolase Human genes 0.000 description 1
- 102100040756 Rhodopsin Human genes 0.000 description 1
- 108090000820 Rhodopsin Proteins 0.000 description 1
- BEBVVQPDSHHWQL-NRPADANISA-N Ser-Val-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O BEBVVQPDSHHWQL-NRPADANISA-N 0.000 description 1
- 208000027073 Stargardt disease Diseases 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 101710159478 Thioredoxin-like protein Proteins 0.000 description 1
- QYSBJAUCUKHSLU-JYJNAYRXSA-N Tyr-Arg-Val Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(O)=O QYSBJAUCUKHSLU-JYJNAYRXSA-N 0.000 description 1
- AEMPCGRFEZTWIF-IHRRRGAJSA-N Val-Leu-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O AEMPCGRFEZTWIF-IHRRRGAJSA-N 0.000 description 1
- SYSWVVCYSXBVJG-RHYQMDGZSA-N Val-Leu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)N)O SYSWVVCYSXBVJG-RHYQMDGZSA-N 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000030597 adult Refsum disease Diseases 0.000 description 1
- 230000006536 aerobic glycolysis Effects 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 108010005233 alanylglutamic acid Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000000453 cell autonomous effect Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000003986 cell retinal photoreceptor Anatomy 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000004456 color vision Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 201000006754 cone-rod dystrophy Diseases 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 108010006664 gamma-glutamyl-glycyl-glycine Proteins 0.000 description 1
- 108010057083 glutamyl-aspartyl-leucine Proteins 0.000 description 1
- 108010062266 glycyl-glycyl-argininal Proteins 0.000 description 1
- 108010026364 glycyl-glycyl-leucine Proteins 0.000 description 1
- 108010050848 glycylleucine Proteins 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 208000017532 inherited retinal dystrophy Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 description 1
- 229960004359 iodixanol Drugs 0.000 description 1
- 108010090333 leucyl-lysyl-proline Proteins 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 108010025153 lysyl-alanyl-alanine Proteins 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 102000004181 nucleoredoxin Human genes 0.000 description 1
- 108010082741 nucleoredoxin Proteins 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 208000014380 ornithine aminotransferase deficiency Diseases 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 238000007128 oxidoreductase reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- MXHCPCSDRGLRER-UHFFFAOYSA-N pentaglycine Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)NCC(O)=O MXHCPCSDRGLRER-UHFFFAOYSA-N 0.000 description 1
- 108010051242 phenylalanylserine Proteins 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 210000000608 photoreceptor cell Anatomy 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 238000013326 plasmid cotransfection Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- -1 repeats Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004243 retinal function Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
- 201000007790 vitelliform macular dystrophy Diseases 0.000 description 1
- 208000020938 vitelliform macular dystrophy 2 Diseases 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/04—Uses of viruses as vector in vivo
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/38—Vector systems having a special element relevant for transcription being a stuffer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
본 발명은 짧거나 및 긴 추체-유도된 간체 생존 인자를 포함하는 개선된 컨스트럭트 및 망막 퇴행성 질환을 치료하는 방법에 관한 것이다.
Description
본 발명은 망막 신경퇴행성 장애, 보다 구체적으로는 신경퇴행성 장애의 치료 및/예방을 위한 약학적 조성물에 관한 것이다.
신경 퇴행성 장애는 신경 퇴행을 특징으로 하는 심각하게 쇠약해진 상태의 범위를 포함한다.
망막 색소변성증(retinitis pigmentosa, RP)과 같은 추체-간체 이영양증 (Rod-cone dystrophy)은 추체(rod) 광수용체의 점진적인 소멸에 이어 간체(cone)의 연속적인 손실을 특징으로 하는 유전적으로 이질적인 망막 퇴행성 질환이다. RP는 세계적으로 약 1:3,500명의 사람들에게 영향을 미치는 유전성 망막 퇴행의 가장 흔한 형태 중 하나이다(참고문헌 1). 63개 이상의 상이한 유전자에서 RP를 유발하는 돌연변이는 지금까지 추체-특이적 전사체에서 상당한 비율로 확인되었다. RP 환자는 황반성 간체-매개 시력(macular cone-mediated vision)의 상대적 보존과 함께, 처음에는 추체 기능 이상의 결과로 흐릿한 광 조건에서 시력 상실을 나타낸다. 그러나 질병이 진행됨에 따라, 추체의 1차 손실은 간체 퇴행, 및 이에 상응하는 간체-매개 시력의 결손이 뒤따른다. 환경의 대부분이 인위적으로 조명되고, 많은 활동이 높은 색채 시력에 의존하는 현대 사회에서 RP 환자의 간체-매개 시력 유지는 삶의 질을 크게 향상시킬 것이다.
추체-특이적 돌연변이에 의해 야기된 RP 서브셋에서의 간체 손실은 완전하게 이해되지는 않지만 반드시 상호 배타적이지 않은 일부 메카니즘이 제안되었다. 일부 가설화된 메커니즘은 간체의 사멸이 주변 추체의 퇴행으로 인한 내독소의 방출의 결과, 또는 추체, 망막 색소 상피 (retinal pigment epithelium, RPE) 또는 뮐러 신경교세포(Muller glia)와의 접촉 상실의 결과로 인한 '이웃 효과(neighbor effect)'임을 시사한다. 대안적으로, 뮐러 세포의 활성화 및 독성 분자의 방출이 역할을 할 수 있다. 다른 가설은 추체의 대사 부하가 상실됨에 따라 맥락막 혈액 순환에서 RPE에 의해 광수용체 층으로 전달되는 산소 또는 레티노이드의 양이 과도하고 유독하다는 것이다 (참고문헌 2). Punzo 등은 망막 퇴행의 마우스 모델에서 라파마이신 경로의 인슐린/포유류 표적에 의해 간체가 기아와 영양 불균형의 결과로 부분적으로 죽는다는 증거를 보여 주었다(참고문헌 3). 또한, 추체에 의해 분비되고 간체 생존에 필요한 생존 인자의 결핍이 간체 손실에 기여할 수 있다고 제안되었다 (참고문헌 4, 5).
마지막 가설과 동일하게, rd1 마우스에서 이식된 건강한 망막 조직은 이식된 조직으로부터 떨어진 부위에서 간체 생존을 지지하는 것으로 나타났다 (참고문헌 6, 7).
국제 특허 출원 WO2008/148860A1은 신경 생존을 증가시킬 수 있고 RP와 같은 신경퇴행성 장애의 치료 및/또는 예방에 유용한 추체-유래 간체 생존 인자 (RdCVF) 및 RdCVF2로 불리는 영양 인자(trophic factor)의 패밀리를 기술한다.
추체-유래 간체 생존 인자 (RdCVF)는 이러한 회복 효과(rescue effect)를 담당하는 후보 분자로서 cDNA 라이브러리를 스크리닝하는 고처리량 방법에서 확인되었다 (참고문헌 4). 추체는 RdCVF를 분비하므로 추체가 사멸하면, 이 주변분비 인자(paracrine factor)의 원천이 사라지고 RdCVF 수준이 감소한다. 따라서, RdCVF의 발현 및 분비된 인자의 손실은 추체-간체 이영양증에서 관찰되는 추체 변성의 2차 급증(wave)에 기여할 수 있다. RdCVF는 배양 (참고문헌 8) 및 망막 색소변성증의 열성 및 우성 형태의 마우스 및 랫트 모델에서 망막하(subretinally)에 주사했을 때 간체 생존을 매개하는 것으로 나타났다 (참고문헌 4, 9). RdCVF를 코딩하는 유전자인 Nxnl1의 파괴는 시간이 지남에 따라 마우스 광수용체가 광수용체 기능 이상 및 간체 손실에 점점 더 민감해지게 한다 (참고문헌 10).
Nxnl1은 상이한 스플라이싱을 통해 2개의 단백질 이소형(isoform)을 코딩한다. 간체 생존을 매개하는 이소형인, RdCVF는 더 긴 카운터파트인 RdCVFL의 변형된 티오레독신-접힘 단백질(truncated thioredoxin-fold protein)이며, RdCVFL은 효소적 티올-산화환원효소(thiol-oxidoreductase) 활성을 부여하는 C-말단 연장을 포함한다 (참고문헌 11). RdCVF의 모든 아미노산을 함유하는 RdCVFL은 Nxnl1 유전자의 엑손 1 및 2에 의해 코딩되며 티오레독신 패밀리의 구성원이다 (참고문헌 12). 티오레독신은 세포에서 적절한 환원 환경을 유지하고, 세포사멸 경로에 참여하는 것을 포함하여 다양한 기능을 갖는다. 이들 기능들은 티오레독신 접힘 내의 보존된 CXXC 촉매 부위에 의해 매개되는 티올산화환원효소 반응을 통해 수행된다 (참고문헌 13).
Byrne 등(참고문헌 32)은 RdCVF의 2개 이소형이 상보적인 기능을 가지고 있음을 보여 주었다. RdCVF를 코딩하는 아데노-관련 바이러스(AAV)의 전신 투여는 간체 기능을 개선하고 간체 손실을 지연시키는 한편, RdCVFL은 로돕신 mRNA를 증가시키고 산화 스트레스를 감소시켰다. RdCVFL은 추체의 광-산화적 손상(photo-oxidative damage)을 방지한다(참고문헌 36).
국제 특허 출원 WO 2016/185037은 RdCVF 및 RdCVFL 모두를 코딩하는 AAV 벡터, 구체적으로 AAV CT35, 및 망막 색소변성증과 같은 질병을 치료하기 위한 상기 벡터의 용도를 기술한다.
RdCVF와 RdCVFL 사이의 시너지 효과가 입증되었다(참고문헌 34). 한편, RdCVF는 망막 색소 상피(RPE)에 의해 생성되고 분비되며, 비-세포 자율 기작(non-cell autonomous mechanism)에 의해 간체의 세포 표면에서 RdCVF 수용체를 통해 호기성 당분해를 자극함으로써 간체를 보호한다(참고문헌 37). 반면 RdCVFL은 티올산화환원효소 기능으로 인해 세포 자율 방식으로 산화적 손상으로부터 간체를 보호한다.
본 발명자들은 그러한 AAV 벡터의 생성이 예기치 않게 AAV 게놈의 캡슐화(encapsidation) 문제를 나타내는 것을 관찰하였다. 불완전한 패키징의 문제는 완전한 게놈을 갖는 AAV 입자의 생산에 결함을 초래한다.
이는 인간 치료에 사용하기 위한 GMP-준수 AAV 벡터의 생산에 대한 제한을 보여준다.
따라서, 망막 신경퇴행성 장애를 치료하기 위해 RdCVF 및 RdCVFL 인자의 발현을 위한 개선된 컨스트럭트가 여전히 필요하다.
본 발명자들은 RdCVF를 코딩하는 제1 핵산 및 RdCVFL을 코딩하는 제2 핵산을 포함하는 단일 AAV 벡터의 생산이 바이러스 캡시드 내에서 AAV 단일 가닥 DNA의 불완전 패키징 문제를 겪을 수 있음을 발견하였다. 이러한 불완전한 캡슐화는 불완전한 AAV 게놈, 즉 더 작은 크기의 DNA의 생산을 초래한다.
본 발명자들은 놀랍게도 이러한 불완전한 캡슐화가 AAV 게놈 내의 직접 반복 서열(direct repeated sequences)의 존재에 기인하고, 제1 발현 카세트와 제2 발현 카세트 사이에서 동일한 뉴클레오티드의 길이를 최대 200개의 연속적으로 동일한 뉴클레오티드(contiguous identical nucleotides)로 제한하면 AAV가 완전히 패키징될 수 있음을 발견하였다.
따라서, 본 발명은 AAV 입자의 생성에 최적화된, RdCVF를 코딩하는 제1 핵산을 포함하는 제1 발현 카세트 및 RdCVFL을 코딩하는 제2 핵산을 포함하는 제2 발현 카세트를 포함하는 AAV 벡터를 제공함으로써 이 문제에 대한 해결책을 제공한다.
본 발명에 따른 AAV는 최대 200개의 연속적으로 동일한 뉴클레오티드, 바람직하게는 최대 190개, 더욱 바람직하게는 최대 180개, 170개, 167개, 165개, 164개, 160개, 150개, 140개, 130개, 120개, 110개, 100개, 90개, 80개, 70개, 60개, 55개, 54개, 50개, 40개, 30개, 20개, 15개, 10개, 9개 또는 8개의 연속적으로 동일한 뉴클레오티드를 보여주는 제1 및 제2 발현 카세트를 포함한다.
본 발명자들은 제1 및 제2 발현 카세트 사이의 직접 반복 서열의 문제점에 대한 몇 가지 대안적인 및/또는 누적적인 해결법을 개발하였다.
따라서, 일 측면에서, 본 발명은
- RdCVF를 코딩하는 제1 핵산을 포함하는 제1 발현 카세트 및
- RdCVFL을 코딩하는 제2 핵산을 포함하는 제2 발현 카세트를 포함하고,
상기 제1 및 제2 발현 카세트는 200개 미만의 연속적으로 동일한 뉴클레오티드를 디스플레이하는 아데노-관련 벡터(AAV)에 관한 것이다.
다른 측면에서, 본 발명은
- RdCVF를 코딩하는 제1 핵산을 포함하는 제1 발현 카세트 및
- RdCVFL을 코딩하는 제2 핵산을 포함하는 제2 발현 카세트를 포함하고,
망막 신경퇴행성 장애의 치료 방법에 사용하기 위한 것이며,
상기 제1 및 제2 발현 카세트는 200개 미만의 연속적으로 동일한 뉴클레오티드를 디스플레이하는 아데노-관련 벡터(AAV)에 관한 것이다.
본 발명은 또한,
- RdCVF를 코딩하는 제1 핵산을 포함하는 제1 발현 카세트 및
- RdCVFL을 코딩하는 제2 핵산을 포함하는 제2 발현 카세트를 포함하고,
상기 제1 및 제2 발현 카세트는 200개 미만의 연속적으로 동일한 뉴클레오티드를 디스플레이하는 아데노-관련 벡터(AAV)의 치료적 유효량을 망막 퇴행성 질환 환자에게 투여하는 것으로 이루어진 단계를 포함하는, 망막 퇴행성 질환 환자의 치료 방법에 관한 것이다.
본 발명은 또한 AAV 컨스트럭트에서 비활성 인간 DNA 서열의 용도에 관한 것이다.
일 측면에서, 본 발명은 서열번호 10으로 표시되는 서열을 갖는 핵산을 포함하는 AAV에 관한 것이며, 상기 서열번호 10으로 표시되는 서열을 갖는 핵산은 발현 카세트에는 존재하지 않는다.
본 발명은 짧거나 및 긴 추체-유도 간체 생존 인자를 포함하는 개선된 컨스트럭트 및 망막 퇴행성 질환을 치료하는 방법에 관한 것이다.
도 1은 본 발명에 따른 바람직한 컨스트럭트의 개략도를 나타낸다: 도 1A는 WO2016/185037에 개시된 비교예인 컨스트럭트 CT35(따라서, 본 발명에 따른 컨스트럭트가 아님)을 나타내고, 도 1B, 1C 및 1D는 각각 본 발명에 따른 컨스트럭트 3 (C03), 6 (C06) 및 11 (C11)을 나타낸다.
도 2는 변성 젤 전기영동으로 분석한 AAV 게놈의 단일 가닥 DNA의 크기를 나타낸다. 상이한 컨스트럭트에서 AAV 게놈의 단일 가닥 DNA의 크기는 변성 조건 하에서 겔 전기 영동에 의해 분석되었다:
-RdCVF 및 RdCVFL을 모두 발현하는 컨스트럭트 3 (C03) (7v7. AAV2-CMV/CBAorig-RdCVF-5'_1.7.OPN1L/MW-RdCVFL);
-RdCVF 및 RdCVFL을 모두 표현하는 CT35 (AAV2-CMV/CBA-RdCVF-CMV/CBA-RdCVFL)(서열번호 15); 및
-RdCVF만 발현하는 CT37(AAV2-CMV/CBA-RdCVF+스터퍼) (서열번호 16).
도 3은 비활성 "스터퍼" DNA에 대한 선택 과정의 개략도를 나타낸다.
도 4는 패키징 비교를 나타낸다.
도 4A는 AAV CT35의 다른 개략도를 나타내며, RdCVF 및 RdCVFL을 모두 발현하는 이러한 AAV에서, 제1 및 제2 발현 카세트는 프로모터[CMV/CBA delta 390]의 직접 반복으로 인해 390개의 연속적으로 동일한 뉴클레오티드를 갖는다.
도 4B는 카세트 [CMV/CBA delta 390-RdCVF]의 제거 또는 카세트 [CMV/CBA delta 390-RdCVFL]와의 재조합을 생성하는 두 카피 [CMV/CBA delta 390] 사이의 재조합에 대한 그래픽 시뮬레이션을 나타낸다.
도 4C는 돼지 색소 상피의 1차 세포에서 CT35 (AAV-CMV/CBA-RdCVF_CMV/CBA-RdCVFL)의 형질 도입(transduction) 및 토끼 다클론성 항-RdCVF 항체(4)를 사용한 RdCVF 및 RdCVFL의 웨스턴 블롯 분석을 나타낸다.
도 4D는 AAV C06의 다른 개략도 및 재조합의 그래픽 시뮬레이션을 나타낸다. 이 AAV에서, 제1 및 제2 발현 카세트는 167개의 연속적으로 동일한 뉴클레오티드의 직접 반복을 공유한다.
도 4E는 AAV C03의 다른 개략도이다.
도 4F는 캡슐화된 AAV C06, C03, CT35 및 CT37 (캡시드 단백질+DNA)의 게놈 완전성(integrity) 분석을 나타낸다.
도 4G 및 4H는 C03 및 C06에 대해 완전한 캡슐화된 AAV(full)를 포함하는 캡시드의 백분율, 불완전하게 캡슐화된 AAV를 포함하는 캡시드의 백분율 (intermediate) 및 AAV를 포함하지 않는 캡시드의 백분율 (empty; DNA 없음)을 나타내는 표이다. 표 4G는 캡시드 단백질 및 DNA (AAV 게놈) 모두에 대해 수득된 검출 결과를 보여주고, 표 4H는 DNA에 대해서만 수득한 검출 결과를 보여준다.
도 2는 변성 젤 전기영동으로 분석한 AAV 게놈의 단일 가닥 DNA의 크기를 나타낸다. 상이한 컨스트럭트에서 AAV 게놈의 단일 가닥 DNA의 크기는 변성 조건 하에서 겔 전기 영동에 의해 분석되었다:
-RdCVF 및 RdCVFL을 모두 발현하는 컨스트럭트 3 (C03) (7v7. AAV2-CMV/CBAorig-RdCVF-5'_1.7.OPN1L/MW-RdCVFL);
-RdCVF 및 RdCVFL을 모두 표현하는 CT35 (AAV2-CMV/CBA-RdCVF-CMV/CBA-RdCVFL)(서열번호 15); 및
-RdCVF만 발현하는 CT37(AAV2-CMV/CBA-RdCVF+스터퍼) (서열번호 16).
도 3은 비활성 "스터퍼" DNA에 대한 선택 과정의 개략도를 나타낸다.
도 4는 패키징 비교를 나타낸다.
도 4A는 AAV CT35의 다른 개략도를 나타내며, RdCVF 및 RdCVFL을 모두 발현하는 이러한 AAV에서, 제1 및 제2 발현 카세트는 프로모터[CMV/CBA delta 390]의 직접 반복으로 인해 390개의 연속적으로 동일한 뉴클레오티드를 갖는다.
도 4B는 카세트 [CMV/CBA delta 390-RdCVF]의 제거 또는 카세트 [CMV/CBA delta 390-RdCVFL]와의 재조합을 생성하는 두 카피 [CMV/CBA delta 390] 사이의 재조합에 대한 그래픽 시뮬레이션을 나타낸다.
도 4C는 돼지 색소 상피의 1차 세포에서 CT35 (AAV-CMV/CBA-RdCVF_CMV/CBA-RdCVFL)의 형질 도입(transduction) 및 토끼 다클론성 항-RdCVF 항체(4)를 사용한 RdCVF 및 RdCVFL의 웨스턴 블롯 분석을 나타낸다.
도 4D는 AAV C06의 다른 개략도 및 재조합의 그래픽 시뮬레이션을 나타낸다. 이 AAV에서, 제1 및 제2 발현 카세트는 167개의 연속적으로 동일한 뉴클레오티드의 직접 반복을 공유한다.
도 4E는 AAV C03의 다른 개략도이다.
도 4F는 캡슐화된 AAV C06, C03, CT35 및 CT37 (캡시드 단백질+DNA)의 게놈 완전성(integrity) 분석을 나타낸다.
도 4G 및 4H는 C03 및 C06에 대해 완전한 캡슐화된 AAV(full)를 포함하는 캡시드의 백분율, 불완전하게 캡슐화된 AAV를 포함하는 캡시드의 백분율 (intermediate) 및 AAV를 포함하지 않는 캡시드의 백분율 (empty; DNA 없음)을 나타내는 표이다. 표 4G는 캡시드 단백질 및 DNA (AAV 게놈) 모두에 대해 수득된 검출 결과를 보여주고, 표 4H는 DNA에 대해서만 수득한 검출 결과를 보여준다.
그러므로, 일 측면에서, 본 발명은
- RdCVF를 코딩하는 제1 핵산을 포함하는 제1 발현 카세트 및
- RdCVFL을 코딩하는 제2 핵산을 포함하는 제2 발현 카세트를 포함하고,
상기 제1 및 제2 발현 카세트는 200개 미만의 연속적으로 동일한 뉴클레오티드를 디스플레이하는 아데노-관련 벡터(AAV)에 관한 것이다.
상기 제1 및 제2 발현 카세트가 200개 미만의 연속적으로 동일한 뉴클레오티드를 디스플레이한다는 사실은 제1 및 제2 발현 카세트가 200개 미만의 연속적으로 동일한 뉴클레오티드를 공통으로 갖는 것을 의미한다.
일반적으로, 상기 제1 및 제2 발현 카세트는 최대 200개의 연속적으로 동일한 뉴클레오티드, 바람직하게는 최대 190개, 더욱 바람직하게는 최대 180개, 170개, 167개, 165개, 164개, 160개, 150개, 140개, 130개, 120개, 110개, 100개, 90개, 80개, 70개, 60개, 55개, 54개, 50개, 40개, 30개, 20개, 15개, 10개, 9개 또는 8개의 연속적으로 동일한 뉴클레오티드를 공유한다.
다른 측면에서, 본 발명은
- RdCVF를 코딩하는 제1 핵산을 포함하는 제1 발현 카세트 및
- RdCVFL을 코딩하는 제2 핵산을 포함하는 제2 발현 카세트를 포함하고,
망막 신경퇴행성 장애의 치료 방법에 사용하기 위한 것이며,
상기 제1 및 제2 발현 카세트는 200개 미만의 연속적으로 동일한 뉴클레오티드를 디스플레이하는 아데노-관련 벡터(AAV)에 관한 것이다.
본 발명은 또한,
- RdCVF를 코딩하는 제1 핵산을 포함하는 제1 발현 카세트 및
- RdCVFL을 코딩하는 제2 핵산을 포함하는 제2 발현 카세트를 포함하고,
상기 제1 및 제2 발현 카세트는 200개 미만의 연속적으로 동일한 뉴클레오티드를 디스플레이하는 아데노-관련 벡터(AAV)의 치료적 유효량을 망막 퇴행성 질환 환자에게 투여하는 것으로 이루어진 단계를 포함하는, 망막 퇴행성 질환 환자의 치료 방법에 관한 것이다.
본 명세서에 사용된, 용어 "추체-유래 간체 생존 인자(rod-derived cone viability factor, RdCVF)는 티오레독신-유사 6 (thioredoxin-like 6, TXNL6) 또는 뉴클레오레독신-유사 1 (Nucleoredoxin-like 1, NXNL1) 유전자에 의해 코딩되는 단백질을 지칭한다. 상기 인자는 모든 동물 종의 RdCVF 단백질을 포함한다. 일반적으로, 본 발명에 따른 RdCVF 단백질은 마우스, 랫트, 고양이, 개, 비인간 영장류 및 인간을 포함하지만 이에 제한되지 않는 포유동물 RdCVF 단백질일 수 있다.
달리 명시되지 않는 한, 용어 "RdCVF"는 NXNL1 유전자의 짧은 이소형을 지칭하고, "RdCVFL" 또는 "RdCVF-L"은 NXNL1 유전자의 긴 이소형을 지칭한다.
일반적으로, 마우스에서, 짧은 이소형(RdCVF)은 Uniprot 식별 번호 Q91W38인 109개 아미노산 길이의 참조 단백질이다. 마우스의 긴 이소형 (RdCVFL)은 Q8VC33에 참조된 217개 아미노산 길이의 단백질이다.
본 발명의 한 실시 양태에서, RdCVF의 짧은 이소형은 다음 서열을 갖는 RdCVF의 인간 짧은 이소형(hRdCVF)이다:
10 20 30 40 50
MASLFSGRIL IRNNSDQDEL DTEAEVSRRL ENRLVLLFFG AGACPQCQAF
60 70 80 90 100
VPILKDFFVR LTDEFYVLRA AQLALVYVSQ DSTEEQQDLF LKDMPKKWLF
109
LPFEDDLRR (서열번호 1)
따라서, RdCVF의 짧은 이소형을 코딩하는 제1 핵산은 하기 인간 핵산 서열을 포함할 수 있다:
ATGGCCTCCCTGTTCTCTGGCCGCATCCTGATCCGCAACAATAGCGACCAGGACGAGCTG
GATACGGAGGCTGAGGTCAGTCGCAGGCTGGAGAACCGGCTGGTGCTGCTGTTCTTTGGT
GCTGGGGCTTGTCCACAGTGCCAGGCCTTCGTGCCCATCCTCAAGGACTTCTTCGTGCGG
CTCACAGATGAGTTCTATGTACTGCGGGCGGCTCAGCTGGCCCTGGTGTACGTGTCCCAG
GACTCCACGGAGGAGCAGCAGGACCTGTTCCTCAAGGACATGCCAAAGAAATGGCTTTTC
CTGCCCTTTGAGGATGATCTGAGGAGGTGA (서열번호 3)
대안적으로, 상기 제1 핵산은 서열번호 3과는 다르지만 동일한 아미노산 서열을 코딩하는 핵산을 포함할 수 있다.
적절한 핵산 서열은 다음을 포함하지만 이에 제한되지는 않는다:
- 인간 RdCVF를 코딩하는 cDNA의 다형성(polymorphisms);
- 인간 RdCVF를 코딩하는 cDNA의 다형성의 조합(희귀 일배체형). 희귀 일배체형(rare haplotypes) cDNA의 예는 서열번호 11로 표시됨;
- 특정 코돈이 동일한 아미노산을 코딩하는 코돈으로 대체되는 "최적화 된" 서열. RdCVF를 코딩하는 적절한 코돈-최적화된 서열은 서열번호 12로 표시되는 서열을 포함하나 이에 제한되지는 않음; 및
- 상동 서열(homologous sequences). 예를 들어, 본 발명자들은 침팬지 RdCVF의 짧은 이소형을 코딩하는 침팬지 cDNA 서열이 사용될 수 있음을 발견하였으며, 이는 인간 cDNA와 동일한 아미노산 서열을 코딩하기 때문이다. 침팬지 cDNA는 서열번호 4로 표시되는 서열을 갖는다.
본 발명의 한 실시 양태에서, NXNL1 유전자의 긴 이소형은 식별 번호 Q96CM4로 참조되고 하기에 제시된 서열을 갖는 인간의 긴 이소형 RdCVFL (hRdCVFL)이다:
10 20 30 40 50
MASLFSGRIL IRNNSDQDEL DTEAEVSRRL ENRLVLLFFG AGACPQCQAF
60 70 80 90 100
VPILKDFFVR LTDEFYVLRA AQLALVYVSQ DSTEEQQDLF LKDMPKKWLF
110 120 130 140 150
LPFEDDLRRD LGRQFSVERL PAVVVLKPDG DVLTRDGADE IQRLGTACFA
160 170 180 190 200
NWQEAAEVLD RNFQLPEDLE DQEPRSLTEC LRRHKYRVEK AARGGRDPGG
210
GGGEEGGAGG LF (서열번호 2)
따라서, RdCVFL을 코딩하는 제2 핵산은 하기 인간 핵산 서열을 포함할 수 있다:
ATGGCCTCCCTGTTCTCTGGCCGCATCCTGATCCGCAACAATAGCGACCAGGACGAGCTG
GATACGGAGGCTGAGGTCAGTCGCAGGCTGGAGAACCGGCTGGTGCTGCTGTTCTTTGGT
GCTGGGGCTTGTCCACAGTGCCAGGCCTTCGTGCCCATCCTCAAGGACTTCTTCGTGCGG
CTCACAGATGAGTTCTATGTACTGCGGGCGGCTCAGCTGGCCCTGGTGTACGTGTCCCAG
GACTCCACGGAGGAGCAGCAGGACCTGTTCCTCAAGGACATGCCAAAGAAATGGCTTTTC
CTGCCCTTTGAGGATGATCTGAGGAGGGACCTCGGGCGCCAGTTCTCAGTGGAGCGCCTG
CCGGCGGTCGTGGTGCTCAAGCCGGACGGGGACGTGCTCACTCGCGACGGCGCCGACGAG
ATCCAGCGCCTGGGCACCGCCTGCTTCGCCAACTGGCAGGAGGCGGCCGAGGTGCTGGAC
CGCAACTTCCAGCTGCCAGAGGACCTGGAGGACCAGGAGCCACGGAGCCTCACCGAGTGC
CTGCGCCGCCACAAGTACCGCGTGGAAAAGGCGGCGCGAGGCGGGCGCGACCCCGGGGGA
GGGGGTGGGGAGGAGGGCGGGGCCGGGGGGCTGTTCTGA (서열번호 5)
대안적으로, 상기 제2 핵산은 서열번호 5와는 다르지만 동일한 아미노산 서열을 코딩하는 핵산을 포함할 수 있다.
적절한 핵산 서열은 다음을 포함하지만 이에 제한되지는 않는다:
-인간 RdCVF를 코딩하는 cDNA의 다형성 또는 이들의 조합;
-특정 코돈이 동일한 아미노산을 코딩하는 코돈으로 대체된 "최적화된" 서열; RdCVF 코딩에 적절한 코돈-최적화된 서열은 서열번호 12로 표시되는 서열을 포함하나, 이에 제한되지는 않음;
-다른 종에서의 상동 서열.
RdCVF 및 RdCVFL 단백질의 서열은 Chalmel et al. 2007(39) 및 국제 특허 출원 WO2008/148860에 제시되어 있다.
본원에 사용된 용어 "아데노-관련 벡터" 또는 "AAV"는 당업계의 일반적인 의미를 갖는다.
AAV는 당업계에서 유전자 전달에 적합한 벡터로 광범위하게 기술되어 있다.
실제로, AAV는 비병원성이며, 혈청형에 따라 광범위한 조직 특이성을 나타낸다. 일반적으로, 본 발명에 따른 AAV는 망막 세포를 표적할 수 있는 AAV이다.
예시는 AAV2, AAV8, AAV2/8, AAV2/5, AAV2/9 및 AAV7m8을 포함하나 이에 제한되지는 않는다.
한 실시 양태에서, 본 발명에 따른 AAV는 국제 특허 출원 WO2012/158757에 기재된 방법에 따라 수득된다.
일반적으로, NXNL1 유전자의 짧은 이소형 및 긴 이소형을 각각 암호화하는 제1 및 제2 핵산은 표적 세포에서 상기 짧은 이소형 및 긴 이소형의 발현을 허용하는 프로모터의 조절 하에 있다.
적합한 프로모터는 CMV/CBA 프로모터와 같은 편재성 프로모터(ubiquitous romoter)일 수 있다.
적합한 프로모터는 망막, 바람직하게는 망막 색소 상피 세포 및 광수용체 세포에서 발현될 수 있는 프로모터일 수 있다.
일 실시양태에서, 상기 프로모터는 망막 색소 상피 세포에서 유전자 발현을 허용한다.
일 실시양태에서, 상기 프로모터는 간체 광수용체에서 유전자 발현을 허용한다. 비제한적 예시는 간체-옵신 프로모터이다.
일반적으로, NXNL1 유전자의 짧은 이소형은 적어도 망막 색소 상피 세포에 의해 발현되고, 긴 이소형은 적어도 간체 광수용체 세포에 의해 발현된다.
본 발명의 일 실시양태에서, 짧은 이소형 및 긴 이소형의 발현을 유도하기 위해 상이한 프로모터가 사용된다.
일반적으로, NXNL1 유전자의 짧은 이소형은 CMV/CBA 프로모터의 조절 하에 발현될 수 있고 NXNL1 유전자의 긴 이소형은 간체-옵신 프로모터의 조절 하에 발현될 수 있다.
본 발명의 일 실시양태에서, 두 발현 카세트는 반전되며(inverted), 하나의 발현 카세트는 5' 내지 3'이고 다른 하나의 발현 카세트는 3' 내지 5'이다.
본 발명자들은 이러한 배열(configuration)이 불완전한 패키징을 피하는데 적합하다는 것을 발견했다.
본 발명의 일 실시양태에서, 상기 기술한 아데노-관련 벡터(AAV)는 서열번호 10의 스터퍼 서열(stuffer sequence)을 추가로 포함한다.
구체적인 실시양태에서, 본 발명은 다음을 포함하는 아데노-관련 벡터 (AAV)에 관한 것이다:
- 편재성 프로모터, 바람직하게는 CMV/CBA 프로모터의 조절 하에서 RdCVF를 코딩하는 코돈-최적화된 cDNA를 포함하는 제1 핵산을 포함하는 제1 발현 카세트; 및
- 간체-옵신 프로포모터(OPN1L/MW)의 조절 하에서 RdCVFL을 코딩하는 코돈-최적화된 cDNA를 포함하는 제2 핵산을 포함하는 제2 발현 카세트.
일 실시양태에서, RdCVF를 코딩하는 코돈-최적화된 cDNA를 포함하는 제1 핵산은 서열번호 12로 표시되는 서열을 갖는다.
일 실시양태에서, RdCVFL을 코딩하는 코돈-최적화된 cDNA를 포함하는 제2 핵산은 서열번호 13으로 표시되는 서열을 갖는다.
일 실시양태에서, 상기 아데노-관련 벡터는 서열번호 6으로 표시되는 서열(하기 실시예의 컨스트럭트 3에 상응)을 갖는다.
본 발명의 내용에서, 본원에 사용된, 용어 "치료(treating 또는 treatment)"는 이러한 용어가 적용되는 장애 또는 상태(예를 들어, 망막 퇴행성 질환), 또는 이러한 장애 또는 상태의 하나 이상의 증상을 역전, 완화, 진행의 억제 또는 예방하는 것을 의미한다.
용어 "망막 퇴행성 질환"은 간체 퇴행과 관련된 모든 질환을 포함한다. 망막 퇴행성 질환에는 망막 색소변성증 (Retinitis Pigmentosa), 노화-관련 황반 변성 (age-related macular degeneration), 바르뎃-바이델 증후군 (Bardet-Biedel syndrome), 바센-코르츠바이크 증후군 (Bassen-Kornzweig syndrome), 베스트 질환 (Best disease), 맥락막 결여(choroidema), 망막 위축 (gyrate atrophy), 레베르 선천성 흑암시 (Leber congenital amaurosis), 레프섬 질환 (Refsum disease), 스타카르트 질환 (Stargardt disease) 또는 어셔 증후군 (Usher syndrome)이 포함되나 이에 제한되지 않는다.
본 발명의 한 실시 양태에서, 상기 망막 퇴행성 질환은 망막 색소변성증이다.
본 발명에 따르면, 용어 "환자" 또는 "필요한 환자"는 망막 퇴행성 질환의 영향을 받거나 영향을 받을 수 있는 인간 또는 비인간 포유 동물을 위한 것이다.
본 발명에 따르면, 조성물의 "치료적 유효량"은 원하는 생물학적 효과를 달성하기에 충분한 양이며, 이 경우 신경 생존을 증가시킨다. 효과적인 투여량(dosage)은 수여자(recipient)의 연령, 성별, 건강 및 체중, 만약 있다면 동시 치료의 종류, 치료 빈도 및 원하는 효과의 성질에 따라 달라질 것으로 이해된다. 그러나 바람직한 투여량은 과도한 실험 없이 당업자에 의해 이해되고 결정될 수 있는 바와 같이 개별 대상에 따라 조정될 수 있다.
본 발명의 발현 벡터는 안내(intraocular) 투여에 적합할 수 있다. 특정 실시 양태에서, 발현 벡터는 망막하 주사(sub-retinal injection)에 의해 투여된다.
일 측면에서, 본 발명은 또한 아데노-관련 벡터 (AAV) 및 약학적으로 허용되는 담체를 포함하는 약학적 조성물에 관한 것으로, 상기 AAV는
- RdCVF를 코딩하는 제1 핵산을 포함하는 제1 발현 카세트 및
- RdCVFL을 코딩하는 제2 핵산을 포함하는 제2 발현 카세트을 포함하고,
상기 제1 및 제2 발현 카세트는 200개 미만의 연속적으로 동일한 뉴클레오티드를 디스플레이한다.
다른 측면에서, 본 발명은 서열번호 10으로 표시되는 서열을 갖는 핵산을 포함하는 AAV에 관한 것이며, 서열번호 10으로 표시되는 서열을 갖는 상기 핵산은 발현 카세트에 존재하지 않는다. 이러한 서열번호 10 서열은 AAV에서 스터퍼 DNA의 역할을 한다. 스터퍼 서열의 역할은 목적 유전자 대신 전바이러스성(proviral) 플라스미드가 캡슐화되는 것을 막기 위해 벡터의 크기를 증가시키는 것이다.
일반적으로 박테리오파지 람다 DNA에 해당하는 스터퍼가 AAV에 사용된다. 그러나 스터퍼로서 가장 일반적으로 사용되는 박테리오파지 람다의 서열은 nin 영역(nin region)이라는 오픈 리딩 프레임을 포함한다. 인간과의 계통 발생 거리 때문에 비활성(inert)으로 간주되지만, Cheng 등(참고문헌 38)은 nin 영역이 강한 전사 활성을 가질 수 있기 때문에 그러한 스터퍼가 예상만큼 비활성이 아님을 입증 하였다. 따라서, 그러한 스터퍼를 갖는 AAV가 인간 환자에게 투여될 때, 박테리오파지 람다 DNA의 전사 위험이 있다.
따라서 새로운 비활성 스터퍼를 개발하는 것이 중요했다. 본 발명자들은 서열번호 10으로 표시되는 서열을 갖는 핵산이 박테리오파지 람다 스터퍼를 대신하여 AAV 컨스트럭트의 크기를 증가시키기 위해 "스터퍼" DNA로 사용될 수 있음을 예기치 않게 발견하였다. 서열번호 10으로 표시되는 서열을 갖는 상기 핵산은 이 서열이 번역되지 않는 서열이고, miRNA 표적이 아니며, 비텔로머성(non-telomeric) 서열이기 때문에 비활성이라는 큰 이점을 가지며, DNA 복제 기점을 포함하지 않고, 뉴클레오티드 반복도 포함하지 않는다. 임의의 기능적 활성을 갖는 이 서열은 AAV에서 스터퍼로서 사용될 때 전사의 위험이 없다.
서열번호 10으로 표시되는 서열은 도 3에 제시된 바와 같은 철저한 과정을 통해 선택되었다. 이는 중심체, 유전자, 유사 유전자(pseudo genes), 복제 원점, 마이크로 RNA 표적화된 서열 또는 반복과 같은 요소와 같은 임의의 요소를 포함하지 않는 인간 게놈 영역을 식별하는 생물정보학적 접근법이다. 이들 유전자좌(loci) 중에서 서열번호 10이 선택되었다.
본 발명은 하기 실시예 및 도면을 통해 추가로 설명될 것이다.
실시예
실시예 1
다음 섹션은 본 발명에 따른 적합한 컨스트럭트의 비제한적 예시를 제공한다.
컨스트럭트 3 (C03):
7v7. AAV2-CMV/CBAorig-RdCVF-5'_1.7.OPN1L/MW-RdCVFL
도 1B에 도시된 바와 같이, 이 컨스트럭트에서, 인간 RdCVF cDNA 서열은 코돈 최적화되고(일차 최적화 과정 v1 사용), 편재성 프로모터인 CMV/CBA 아래에 배치된다. 인간 RdCVFL cDNA 또한 코돈 최적화되고(다른 최적화 과정 v2 사용) 간체-옵신 프로모터의 제어 하에 배치된다. 제1 및 제2 발현 카세트 사이에 공유되는 직접 반복은 9개 뉴클레오티드 길이이다.
상기 AAV 벡터는 서열번호 6으로 표시되는 서열을 갖는다.
컨스트럭트 6 (C06):
AAV2_CMV/CBA_orig_RdCVF_chimp_5p_1.7_OPN1LMW_RdCVFL
도 1C 및 4D에 도시된 바와 같이, 이 컨스트럭트에서, 침팬지 RdCVF cDNA 서열은 제1 발현 카세트에 사용되었고 편재성 프로모터인 CMV/CBA 아래에 배치된다. 인간 RdCVFL cDNA는 간체-옵신 프로모터의 제어 하에 배치된다. 제1 및 제2 발현 카세트 사이에 공유되는 직접 반복은 167개 뉴클레오티드 길이이다.
상기 AAV 벡터는 서열번호 7로 표시되는 서열을 갖는다.
컨스트럭트 7 (C07):
AAV2_rev_CMV/CBA_orig_RdCVF_chimp_5p_1.7_OPN1LMW_RdCVFL
이 컨스트럭트는 제1 발현 카세트가 역 배향(reverse orientation)으로 배치되는 것을 제외하고 컨스트럭트 6과 유사하다.
상기 AAV 벡터는 서열번호 8로 표시되는 서열을 갖는다.
컨스트럭트 8 (C08):
AAV2_CMV/CBA_orig_RdCVF_chimp_rev_5p_1.7_OPN1LMW_RdCVFL-hGH
이 컨스트럭트는 제2 발현 카세트가 역 배향으로 배치되는 것을 제외하고 컨스트럭트 6과 유사하다.
상기 AAV 벡터는 서열번호 9로 표시되는 서열을 갖는다.
컨스트럭트 11 (C11):
AAV2_CMV/CBA_orig_RdCVF_rare_haplotype_human_5p_1.7_OPN1LMW_RdCVFL
도 1D에 도시된 바와 같이, 이 컨스트럭트에서, 제1 발현 카세트는 편재성 프로모터인 CMV/CBA 하에서 다형성의 조합(희귀 일배체형)인 인간 RdCVF를 코딩하는 cDNA를 포함한다. 제2 발현 카세트는 간체-옵신 프로모터의 제어 하에 인간 RdCVFL cDNA를 포함한다. 제1 및 제2 발현 카세트 사이에 공유되는 직접 반복은 54개 뉴클레오티드 길이이다.
상기 AAV 벡터는 서열번호 14로 표시되는 서열을 갖는다.
실시예 2: 동일한 뉴클레오타이드의 긴 스트레치를 보여주는 AAV 구축물은 불완전한 패키징을 받는다.
물질 및 방법
바이러스성 벡터의 생성
마우스-RdCVF, RdCVFL 또는 eGFP를 코딩하는 cDNA를 보유하는 AAV 벡터는 플라스미드 공동-형질감염 방법(참고문헌 31)으로 생성하였다. 재조합 AAV는 염화 세슘 또는 이오딕사놀(iodixanol) 구배 초원심분리로 정제하였다. 바이러스성 용리액을 완충액 교환하고 PBS에서 Amicon Ultra-15 Centrifugal Filter Unit으로 농축하였으며 표준 곡선에 대한 정량적 PCR로 적정하였다.
변성 젤 전기영동
게놈 DNA를 추출하고 변성 젤 전기영동에 적용하였다. 핵산의 크기는 DNA 사다리와 비교하였다.
결과
도 2 및 4F는 WO2016/185037에 개시된 컨스트럭트 CT37이고 따라서 본 발명에 따른 컨스트럭트는 아님을 보여준다. RdCVF만 발현하는 이 비교 예시는 이의 생산이 ~ 5000 bp 예상 크기의 DNA를 초래하기 때문에 완전한 패키징이 될 수 있다.
도 2 및 4F에 도시된 바와 같이, 390개의 연속적으로 동일한 뉴클레오티드의 반복을 포함하는 CT35(도 4A)는 이의 생산이 4804 bp의 AAV 게놈 대신에 비정상적인 AAV 게놈 크기를 초래하기 때문에 불완전한 패키징이 될 수 있다.
따라서, AAV에서 RdCVF를 코딩하는 제1 핵산 및 RdCVFL을 코딩하는 제2 핵산을 발현시키는 것은 바이러스성 캡시드에서 AAV 단일 가닥 DNA의 불완전한 캡슐화를 야기할 수 있다는 것을 잘 알 수 있다.
대조적으로, RdCVF 및 RdCVFL 모두를 발현하고 단지 167개 뉴클레오티드 길이의 직접 반복을 포함하는 본 발명에 따른 컨스트럭트 C06은 4942 bp의 예상 크기에서 밴드를 나타낸다. 이 결과는 컨스트럭트 C06의 완전한 캡슐화를 입증한다.
동일한 방식으로, 9개의 연속적으로 동일한 뉴클레오티드의 반복을 포함하는 컨스트럭트 C03은 4926 bp의 예상 크기에서 단일 밴드를 나타낸다.
2개의 발현 카세트 사이에 공유되는 연속적으로 동일한 뉴클레오티드의 수를 감소시키면, RdCVF를 코딩하는 핵산 및 RdCVFL을 코딩하는 핵산 모두를 포함하는 AAV의 완전한 캡슐화의 비율을 증가시킬 수 있는 것으로 나타났다.
따라서, 본 발명자들은 제1 및 제2 발현 카세트가 200개를 초과하는 연속적인 핵산을 함유하지 않을 때 완전한 패키징이 얻어진다는 것을 입증하였다.
이러한 현상을 추가로 탐구하기 위해, 상이한 컨스트럭트의 비교에 Burnham 등(참고문헌 35)에 따른 분석적 초원심분리를 사용하였다 (도 4G 및 4H). C03 및 C06에 대한 결과는 변성 겔에서 관찰된 여분 밴드(extra band)가 가득 찬 것과 비어있는 것 사이의 입자를 나타내는 중간 침강 계수를 갖는 AAV 입자의 높은 비율과 일치하고, 따라서 불완전하게 패키지된 AAV를 포함하는 입자에 해당함을 보여준다. 변성 겔 전기영동에서 얻은 결과에 따라, 컨스트럭트 C06은 18%의 완전한 캡슐화를 나타내고, 컨스트럭트 C03은 분석적 초원심분리 방법에서 적절한 결과를 산출하였으며, 완전한 AAV 입자의 높은 퍼센트(58%)를 나타냈다 (도 4H).
이는 두 발현 카세트 사이에 공유되는 연속적으로 동일한 뉴클레오티드의 수가 200개를 초과하지 않을 때, 온전한 게놈(integral genome)을 갖는 입자의 백분율이 증가함을 확인시켜 준다.
실시예 3: RdCVF 및 RdCVFL의 조합은 시너지 효과를 초래한다
다음 컨스트를 생성하여 AAV2 벡터에 도입하였다.
전바이러스성 플라스미드 p618 및 이의 요소는 WO2012158757A1로 공개된 국제 특허 출원 및 공개문헌(참고문헌 33)에 기재되어 있다.
2xRdCVF: 플라스미드 p857 및 AAV CT39
P857/CT39는 망막 색소변성증 (RP)을 앓고 있는 환자에서 충분한 간체 보호를 달성하기 위해 CT37 (RdCVF-스터퍼)에 비해 RdCVF의 발현 수준이 증가하도록 설계되었다.
RdCVF-RdCVFL: 플라스미드 p853 및 AAV CT35
이 벡터는 RdCVF의 짧은 이소형 및 긴 이소형을 공동 발현할 수 있다.
그러나 그 생산은 치료제로서의 사용을 제한하는 비정상적인 불완전한 패키징을 받을 수 있다.
실시예 4: 파지 람다 스터퍼를 대체하기 위한 비활성 DNA의 선별
본 발명자들은 충분한 크기를 갖는 AAV 컨스트럭트를 수득하기 위해 전통적으로 사용된 파지 람다 스터퍼 서열에 대해 보다 안전한 대안으로 사용될 수 있는 핵산 서열을 동정하는 스크리닝 공정을 개발하였다.
중심체, 공지된 유전자, 유사 유전자, 반복, miRNA 표적, 복제 원점과 같은 원하지 않는 서열을 제거하기 위해 전체 인간 게놈의 스크리닝을 수행하였다. 본 발명의 스크리닝 공정은 인간 염색체 15로부터 불활성 서열인 서열번호 10의 선택을 초래하였다.
실시예 5: 재조합 분석
도 4C에서의 웨스턴 블롯 분석은 토끼 다클론성 항-RdCVF 항체를 사용하여 RdCVF 및 RdCVFL의 발현을 보여준다. CT35가 상동 재조합에 적용되지 않음을 입증하는 컨스트럭트 CT35에서 두 단백질이 검출된다.
[참고문헌]
본 출원 전반에 걸쳐, 다양한 참고문헌이 본 발명이 속하는 기술 분야를 기술한다. 이들 참고문헌의 개시는 본원에 참고로 포함된다.
1. Buch H et al. Prevalence and causes of visual impairment and blindness among 9980 Scandinavian adults: the Copenhagen City Eye Study. Ophthalmology. 2004;111(1):53-61.
2. Bramall AN, Wright AF, Jacobson SG, McInnes RR. The genomic, biochemical, and cellular responses of the retina in inherited photoreceptor degenerations and prospects for the treatment of these disorders. Annu Rev Neurosci. 2010;33(1):441-472.
3. Punzo C, Kornacker K, Cepko CL. Stimulation of the insulin/mTOR pathway delays cone death in a mouse model of retinitis pigmentosa. Nat Neurosci. 2009;12(1):44-52.
4. Lιveillard T et al. Identification and characterization of rod-derived cone viability factor. Nat Genet. 2004;36(7):755-759.
5. Mohand-Said S et al. Normal retina releases a diffusible factor stimulating cone survival in the retinal degeneration mouse. Proc Natl Acad Sci U S A. 1998;95(14):8357-8362.
6. Mohand-Said S et al. Photoreceptor transplants increase host cone survival in the retinal degeneration (rd) mouse. Ophthalmic Res. 1997;29(5):290-297.
7. Mohand-Said S, Hicks D, Dreyfus H, Sahel J-A. Selective transplantation of rods delays cone loss in a retinitis pigmentosa model. Arch Ophthalmol. 2000;118(6):807-811.
8. Wang XW, Tan BZ, Sun M, Ho B, Ding JL. Thioredoxin-like 6 protects retinal cell line from photooxidative damage by upregulating NF-kappaB activity. Free Radic Biol Med. 2008;45(3):336-344.
9. Yang Y et al. Functional Cone Rescue by RdCVF Protein in a Dominant Model of Retinitis Pigmentosa. Mol Ther. 2009;17(5):787-795.
10. Cronin T et al. The disruption of the rod-derived cone viability gene leads to photoreceptor dysfunction and susceptibility to oxidative stress. Cell Death Differ. 2010;17(7):1199-1210.
11. Brennan LA, Lee W, Kantorow M. TXNL6 is a novel oxidative stress-induced reducing system for methionine sulfoxide reductase a repair of α-crystallin and cytochrome C in the eye lens. PLoS ONE. [published online ahead of print: 2010]; doi:10.1371/journal.pone.0015421.g008
12. Funato Y, Miki H. Nucleoredoxin, a Novel Thioredoxin Family Member Involved in Cell Growth and Differentiation. Antioxid Redox Signal. 2007;9(8):1035-1058.
13. Lillig CH, Holmgren A. Thioredoxin and Related Molecules-From Biology to Health and Disease. Antioxid Redox Signal. 2007;9(1):25-47.
14. Barhoum R et al. Functional and structural modifications during retinal degeneration in the rd10 mouse. Neuroscience. 2008;155(3):698-713.
15. Phillips MJ, Otteson DC, Sherry DM. Progression of neuronal and synaptic remodeling in the rd10mouse model of retinitis pigmentosa. J Comp Neurol. 2010;518(11):2071-2089.
16. Gargini C et al. Retinal organization in the retinal degeneration 10 (rd10) mutant mouse: A morphological and ERG study. J Comp Neurol. 2006;500(2):222-238.
17. Pang JJ et al. AAV-mediated gene therapy for retinal degeneration in the rd10 mouse containing a recessive PDEbeta mutation. Investigative Ophthalmology & Visual Science. 2008;49(10):4278-4283.
18. Pang JJ et al. Long-term retinal function and structure rescue using capsid mutant AAV8 vector in the rd10 mouse, a model of recessive retinitis pigmentosa. Mol Ther. 2011;19(2):234-242.
19. Komeima K, Rogers BS, Campochiaro PA. Antioxidants slow photoreceptor cell death in mouse models of retinitis pigmentosa. J Cell Physiol. 2007;213(3):809-815.
20. Dalkara D et al. In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous. Science Translational Medicine. 2013;5(189):189ra76.
21. Dalkara D et al. Enhanced gene delivery to the neonatal retina through systemic administration of tyrosine-mutated AAV9. Gene Ther. 2012;19(2):176-181.
22. Cao W, Wen R, Li F, Lavail MM, Steinberg RH. Mechanical injury increases bFGF and CNTF mRNA expression in the mouse retina. Experimental Eye Research. 1997;65(2):241-248.
23. Hollander den AI, Black A, Bennett J, Cremers FPM. Lighting a candle in the dark: advances in genetics and gene therapy of recessive retinal dystrophies. J Clin Invest. 2010;120(9):3042-3053.
24. Maguire AM et al. Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis. N Engl J Med. 2008;358(21):2240-2248.
25. Cideciyan AV et al. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proceedings of the National Academy of Sciences. 2008;105(39):15112-15117.
26. Bainbridge JWB et al. Effect of Gene Therapy on Visual Function in Leber's Congenital Amaurosis. N Engl J Med. 2008;358(21):2231-2239.
27. Fridlich R et al. The Thioredoxin-like Protein Rod-derived Cone Viability Factor (RdCVFL) Interacts with TAU and Inhibits Its Phosphorylation in the Retina. Molecular & Cellular Proteomics. 2009;8(6):1206-1218.
28. Mingozzi F et al. CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat Med. 2007;13(4):419-422.
29. Manno CS et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med. 2006;12(3):342-347.
30. Jacobson SG et al. Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. Arch Ophthalmol. 2012;130(1):9-24.
31. Grieger JC, Choi VW, Samulski RJ. Production and characterization of adeno-associated viral vectors. Nat Protoc. 2006;1(3):1412-1428.
32. Byrne LC, Dalkara D, Luna G, Fisher SK, Clιrin E, Sahel JA, Lιveillard T, Flannery JG. Viral-mediated RdCVF and RdCVFL expression protects cone and rod photoreceptors in retinal degeneration. J Clin Invest. 2015 125(1):105-16.
33. Vasireddy, V., Mills, J.A., Gaddameedi, R., Basner-Tschakarjan, E., Kohnke, M., Black, A.H., Alexandrov, K., Maguire, A.M., Chung, D.C., Mac, H., Sullivan, L., Gadue, P., Bennicelli, J.L., French, D.L., and Bennett, J. AAV-mediated gene therapy for choroideremia: Preclinical studies in personalized models. PLoS ONE 01/2013; 8(5):e61396.
34. Mei X., Chaffiol, A., Kole, C., Yang Y., Millet-Puel G., Clerin E., Ait-Ali N., Bennett, J., Dalkara D., Sahel JA, Duebel, J., Lιveillard T., The thioredoxin encoded by the Rod-derived Cone Viability Factor gene protects cone photoreceptors against oxidative stress. Antioxid Redox Signal. 2016 May 12. [Epub ahead of print].
35. Burnham B, Nass S, Kong E, Mattingly M, Woodcock D, Song A, Wadsworth S, Cheng SH, Scaria A, O'Riordan CR: Analytical Ultracentrifugation as an Approach to Characterize Recombinant Adeno-Associated Viral Vectors. Human gene therapy methods 2015, 26(6):228-242.
36. Elachouri G, Lee-Rivera I, Clerin E, Argentini M, Fridlich R, Blond F, Ferracane V, Yang Y, Raffelsberger W, Wan J, Bennett J, Sahel JA, Zack DJ, Leveillard T: Thioredoxin rod-derived cone viability factor protects against photooxidative retinal damage. Free radical biology & medicine 2015, 81:22-29.
37. Ait-Ali N, Fridlich R, Millet-Puel G, Clerin E, Delalande F, Jaillard C, Blond F, Perrocheau L, Reichman S, Byrne LC, Olivier-Bandini A, Bellalou J, Moyse E, Bouillaud F, Nicol X, Dalkara D, van Dorsselaer A, Sahel JA, Leveillard T: Rod-derived cone viability factor promotes cone survival by stimulating aerobic glycolysis. Cell 2015, 161(4):817-832.
38. Cheng SW, Court DL, Friedman DI: Transcription termination signals in the nin region of bacteriophage lambda: identification of Rho-dependent termination regions. Genetics 1995, 140(3):875-887.
39. Chalmel, F., Leveillard, T., Jaillard, C., Lardenois, A., Berdugo, N., Morel, E., Koehl, P., Lambrou, G., Holmgren, A., Sahel, J.A., and Poch, O.(2007). Rod-derived Cone Viability Factor-2 is a novel bifunctional-thioredoxin-like protein with therapeutic potential. BMC molecular biology 8, 74.
<110> SparingVision et al.
<120> Constructs comprising neuronal viability factors and uses thereof
<130> BCT180479QT
<150> EP17306915.4
<151> 2017-12-22
<160> 16
<170> PatentIn version 3.5
<210> 1
<211> 109
<212> PRT
<213> Homo sapiens
<400> 1
Met Ala Ser Leu Phe Ser Gly Arg Ile Leu Ile Arg Asn Asn Ser Asp
1 5 10 15
Gln Asp Glu Leu Asp Thr Glu Ala Glu Val Ser Arg Arg Leu Glu Asn
20 25 30
Arg Leu Val Leu Leu Phe Phe Gly Ala Gly Ala Cys Pro Gln Cys Gln
35 40 45
Ala Phe Val Pro Ile Leu Lys Asp Phe Phe Val Arg Leu Thr Asp Glu
50 55 60
Phe Tyr Val Leu Arg Ala Ala Gln Leu Ala Leu Val Tyr Val Ser Gln
65 70 75 80
Asp Ser Thr Glu Glu Gln Gln Asp Leu Phe Leu Lys Asp Met Pro Lys
85 90 95
Lys Trp Leu Phe Leu Pro Phe Glu Asp Asp Leu Arg Arg
100 105
<210> 2
<211> 212
<212> PRT
<213> Homo sapiens
<400> 2
Met Ala Ser Leu Phe Ser Gly Arg Ile Leu Ile Arg Asn Asn Ser Asp
1 5 10 15
Gln Asp Glu Leu Asp Thr Glu Ala Glu Val Ser Arg Arg Leu Glu Asn
20 25 30
Arg Leu Val Leu Leu Phe Phe Gly Ala Gly Ala Cys Pro Gln Cys Gln
35 40 45
Ala Phe Val Pro Ile Leu Lys Asp Phe Phe Val Arg Leu Thr Asp Glu
50 55 60
Phe Tyr Val Leu Arg Ala Ala Gln Leu Ala Leu Val Tyr Val Ser Gln
65 70 75 80
Asp Ser Thr Glu Glu Gln Gln Asp Leu Phe Leu Lys Asp Met Pro Lys
85 90 95
Lys Trp Leu Phe Leu Pro Phe Glu Asp Asp Leu Arg Arg Asp Leu Gly
100 105 110
Arg Gln Phe Ser Val Glu Arg Leu Pro Ala Val Val Val Leu Lys Pro
115 120 125
Asp Gly Asp Val Leu Thr Arg Asp Gly Ala Asp Glu Ile Gln Arg Leu
130 135 140
Gly Thr Ala Cys Phe Ala Asn Trp Gln Glu Ala Ala Glu Val Leu Asp
145 150 155 160
Arg Asn Phe Gln Leu Pro Glu Asp Leu Glu Asp Gln Glu Pro Arg Ser
165 170 175
Leu Thr Glu Cys Leu Arg Arg His Lys Tyr Arg Val Glu Lys Ala Ala
180 185 190
Arg Gly Gly Arg Asp Pro Gly Gly Gly Gly Gly Glu Glu Gly Gly Ala
195 200 205
Gly Gly Leu Phe
210
<210> 3
<211> 330
<212> DNA
<213> Homo sapiens
<400> 3
atggcctccc tgttctctgg ccgcatcctg atccgcaaca atagcgacca ggacgagctg 60
gatacggagg ctgaggtcag tcgcaggctg gagaaccggc tggtgctgct gttctttggt 120
gctggggctt gtccacagtg ccaggccttc gtgcccatcc tcaaggactt cttcgtgcgg 180
ctcacagatg agttctatgt actgcgggcg gctcagctgg ccctggtgta cgtgtcccag 240
gactccacgg aggagcagca ggacctgttc ctcaaggaca tgccaaagaa atggcttttc 300
ctgccctttg aggatgatct gaggaggtga 330
<210> 4
<211> 330
<212> DNA
<213> Pan troglodytes
<400> 4
atggcctccc tgttctctgg ccgcatcctg atccgcaaca atagcgacca ggacgaactg 60
gatacggagg ctgaggtcag tcgcaggctg gagaaccggc tggtgctgct gttctttggt 120
gccggggctt gtccacagtg ccaggccttc gtgcccatcc tcaaggactt cttcgtgcgg 180
ctcacagatg agttctatgt actgcgggcg gctcagctgg ccctggtgta cgtgtcccag 240
gactccacgg aggagcagca ggacctgttc ctcaaggaca tgccaaagaa gtggcttttc 300
ctgccctttg aggatgatct gaggaggtga 330
<210> 5
<211> 639
<212> DNA
<213> Homo sapiens
<400> 5
atggcctccc tgttctctgg ccgcatcctg atccgcaaca atagcgacca ggacgagctg 60
gatacggagg ctgaggtcag tcgcaggctg gagaaccggc tggtgctgct gttctttggt 120
gctggggctt gtccacagtg ccaggccttc gtgcccatcc tcaaggactt cttcgtgcgg 180
ctcacagatg agttctatgt actgcgggcg gctcagctgg ccctggtgta cgtgtcccag 240
gactccacgg aggagcagca ggacctgttc ctcaaggaca tgccaaagaa atggcttttc 300
ctgccctttg aggatgatct gaggagggac ctcgggcgcc agttctcagt ggagcgcctg 360
ccggcggtcg tggtgctcaa gccggacggg gacgtgctca ctcgcgacgg cgccgacgag 420
atccagcgcc tgggcaccgc ctgcttcgcc aactggcagg aggcggccga ggtgctggac 480
cgcaacttcc agctgccaga ggacctggag gaccaggagc cacggagcct caccgagtgc 540
ctgcgccgcc acaagtaccg cgtggaaaag gcggcgcgag gcgggcgcga ccccggggga 600
gggggtgggg aggagggcgg ggccgggggg ctgttctga 639
<210> 6
<211> 4926
<212> DNA
<213> Artificial Sequence
<220>
<223> construct 3
<400> 6
ttggccactc cctctctgcg cgctcgctcg ctcactgagg ccgggcgacc aaaggtcgcc 60
cgacgcccgg gctttgcccg ggcggcctca gtgagcgagc gagcgcgcag agagggagtg 120
gccaactcca tcactagggg ttcctgacat tgattattga ctagttatta atagtaatca 180
attacggggt cattagttca tagcccatat atggagttcc gcgttacata acttacggta 240
aatggcccgc ctggctgacc gcccaacgac ccccgcccat tgacgtcaat aatgacgtat 300
gttcccatag taacgccaat agggactttc cattgacgtc aatgggtgga gtatttacgg 360
taaactgccc acttggcagt acatcaagtg tatcatatgc caagtacgcc ccctattgac 420
gtcaatgacg gtaaatggcc cgcctggcat tatgcccagt acatgacctt atgggacttt 480
cctacttggc agtacatcta cgtattagtc atcgctatta ccatcgaggt gagccccacg 540
ttctgcttca ctctccccat ctcccccccc tccccacccc caattttgta tttatttatt 600
ttttaattat tttgtgcagc gatgggggcg gggggggggg gggcgcgcgc caggcggggc 660
ggggcggggc gaggggcggg gcggggcgag gcggagaggt gcggcggcag ccaatcagag 720
cggcgcgctc cgaaagtttc cttttatggc gaggcggcgg cggcggcggc cctataaaaa 780
gcgaagcgcg cggcgggcgg gagtcgctgc gttgccttcg ccccgtgccc cgctccgcgc 840
cgcctcgcgc cgcccgcccc ggctctgact gaccgcgtta ctcccacagg tgagcgggcg 900
ggatgagcac ggcccggctt cgggtgcggg gctccgtgcg gggcgtggcg cggggctcgc 960
cgtgccgggc ggggggtggc ggcaggtggg ggtgccgggc ggggcggggc cgcctcgggc 1020
cggggagggc tcgggggagg ggcgcggcgg ccccggagcg ccggcggctg tcgaggcgcg 1080
gcgagccgca gccattgcct tttatggtaa tcgtgcgaga gggcgcaggg acttcctttg 1140
tcccaaatct ggcggagccg aaatctggga ggcgccgccg caccccctct agcgggcgcg 1200
ggcgaagcgg tgcggcgccg gcaggaagga actgggcggg gagggccttc gtgcgtcgcc 1260
gcgccgccgt ccccttctcc atctccagcc tcggggctgc cgcaggggga cggctgcctt 1320
cgggggggac ggggcagggc ggggttcggc ttctggcgtg tgaccggcgg cctctgctaa 1380
ccatgttcat gccttcttct ttttcctaca gctcctgggc aacgtgctgg ttattgtgct 1440
gtctcatcat tttggcaaag aattgccgcc accatggcca gcctcttctc cggacgcatc 1500
ctgattcgca acaattccga ccaagacgaa ctggataccg aggccgaagt ctcgcggaga 1560
ttggagaaca ggcttgtgct gctgttcttt ggcgcgggag cgtgtcctca gtgccaggct 1620
ttcgtgccaa tcctgaagga tttcttcgtg cggctgactg acgaattcta cgtcctccgg 1680
gccgcccagc tggcactggt gtacgtgtcc caagactcaa ccgaggaaca gcaggatctg 1740
ttcctcaagg acatgcccaa aaagtggctg ttcctgccgt ttgaggacga cttgcggcgc 1800
tagaataaaa gatctttatt ttcattagat ctgtgtgttg gttttttgtg tgatgtccct 1860
tatggtgctt ctggctctgc agttattagc atagtgttac catcaaccac cttaacttca 1920
tttttcttat tcaataccta ggtaggtaga tgctagattc tggaaataaa atatgagtct 1980
caagtggtcc ttgtcctctc tcccagtcaa attctgaatc tagttggcaa gattctgaaa 2040
tcaaggcata taatcagtaa taagtgatga tagaagggta tatagaagaa ttttattata 2100
tgagagggtg aaaccctcaa aatgaaatga aatcagaccc ttgtcttaca ccataaacaa 2160
aaataaattt gaatgggtta aagaattaaa ctaagaccta aaaccataaa aatttttaaa 2220
gaaatcaaaa gaagaaaatt ctaatattca cgttgcagcc gttttttgaa tttgatatga 2280
gaagcaaagg caacaaggag gctgaggggt ggggaaaggg catgggtgtt tcatgaggac 2340
agagcttccg tttcatgcaa tgaaaagagt ttggagacgg atggtggtga ctggactata 2400
cacttacaca cggtagcgat ggtacacttt gtattatgta tattttacca cgatcttttt 2460
aaagtgtcaa aggcaaatgg ccaaatggtt ccttgtccta tagctgtagc agccatcggc 2520
tgttagtgac aaagcccctg agtcaagatg acagcagccc ccataactcc taatcggctc 2580
tcccgcgtgg agtcatttag gagtagtcgc attagagaca agtccaacat ctaatcttcc 2640
accctggcca gggccccagc tggcagcgag ggtgggagac tccgggcaga gcagagggcg 2700
ctgacattgg ggcccggcct ggcttgggtc cctctggcct ttccccaggg gccctctttc 2760
cttggggctt tcttgggccg ccactgctcc cgctcctctc cccccatccc accccctcac 2820
cccctcgttc ttcatatcct tctctagtgc tccctccact ttcatccacc cttctgcaag 2880
agtgtgggac cacaaatgag ttttcacctg gcctggggac acacgtgccc ccacaggtgc 2940
tgagtgactt tctaggacag taatctgctt taggctaaaa tgggacttga tcttctgtta 3000
gccctaatca tcaattagca gagccggtga aggtgcagaa cctaccgcct ttccaggcct 3060
cctcccacct ctgccacctc cactctcctt cctgggatgt gggggctggc acacgtgtgg 3120
cccagggcat tggtgggatt gcactgagct gggtcattag cgtaatcctg gacaagggca 3180
gacagggcga gcggagggcc agctccgggg ctcaggcaag gctgggggct tcccccagac 3240
accccactcc tcctctgctg gacccccact tcatagggca cttcgtgttc tcaaagggct 3300
tccaaatagc atggtggcct tggatgccca gggaagcctc agagttgctt atctccctct 3360
agacagaagg ggaatctcgg tcaagaggga gaggtcgccc tgttcaaggc cacccagcca 3420
gctcatggcg gtaatgggac aaggctggcc agccatccca ccctcagaag ggacccggtg 3480
gggcaggtga tctcagagga ggctcacttc tgggtctcac attcttggat ccggttccag 3540
gcctcggccc taaatagtct ccctgggctt tcaagagaac cacatgagaa aggaggattc 3600
gggctctgag cagtttcacc acccaccccc cagtctgcaa atcctgaccc gtgggtccac 3660
ctgccccaaa ggcggacgca ggacagtaga agggaacaga gaacacataa acacagagag 3720
ggccacagcg gctcccacag tcaccgccac cttcctggcg gggatgggtg gggcgtctga 3780
gtttggttcc cagcaaatcc ctctgagccg cccttgcggg ctcgcctcag gagcagggga 3840
gcaagaggtg ggaggaggag gtctaagtcc caggcccaat taagagatca ggtagtgtag 3900
ggtttgggag cttttaaggt gaagaggccc gggctgatcc cacaggccag tataaagcgc 3960
cgtgaccctc aggtgatgcg ccagggccgg ctgccgtcgg ggacagggct ttccatagcc 4020
atggcctcac tgttctccgg gcgcatcctc atccgaaaca acagcgatca ggacgaattg 4080
gacaccgagg ctgaagtctc ccgccggctg gaaaacaggc tcgtgctcct gttcttcggt 4140
gccggagcgt gcccgcagtg ccaagccttc gtcccaattc ttaaggactt ctttgtgcgc 4200
ctcactgatg agttttacgt gctccgggca gcgcagctgg ccttggtgta tgtgtcgcaa 4260
gattccactg aggaacaaca ggacctgttc ctgaaagaca tgcctaagaa gtggcttttc 4320
ctgcccttcg aggacgacct gagaagggac ctgggacgcc agttcagcgt ggaacggctg 4380
ccggccgtcg tggtgctgaa gcccgacggg gacgtgctta cccgggatgg cgctgacgaa 4440
atccagaggc tgggcaccgc ctgtttcgca aattggcagg aggccgccga agtgctcgac 4500
cggaacttcc agctgcccga ggatctggag gaccaggaac ctcggtccct gaccgagtgc 4560
ctcagacgcc acaagtaccg cgtggaaaag gccgcgagag gaggacggga cccgggtggc 4620
gggggaggcg aagagggcgg agccggtggc ctgttctgaa acttgtttat tgcagcttat 4680
aatggttaca aataaagcaa tagcatcaca aatttcacaa ataaagcatt tttttcactg 4740
cattctagtt gtggtttgtc caaactcatc aatgtatctt aaggaacccc tagtgatgga 4800
gttggccact ccctctctgc gcgctcgctc gctcactgag gccgggcgac caaaggtcgc 4860
ccgacgcccg ggctttgccc gggcggcctc agtgagcgag cgagcgcgca gagagggagt 4920
ggccaa 4926
<210> 7
<211> 4942
<212> DNA
<213> Artificial Sequence
<220>
<223> construct 6
<400> 7
gcggccgctt ggccactccc tctctgcgcg ctcgctcgct cactgaggcc gggcgaccaa 60
aggtcgcccg acgcccgggc tttgcccggg cggcctcagt gagcgagcga gcgcgcagag 120
agggagtggc caactccatc actaggggtt cctgacattg attattgact agttattaat 180
agtaatcaat tacggggtca ttagttcata gcccatatat ggagttccgc gttacataac 240
ttacggtaaa tggcccgcct ggctgaccgc ccaacgaccc ccgcccattg acgtcaataa 300
tgacgtatgt tcccatagta acgccaatag ggactttcca ttgacgtcaa tgggtggagt 360
atttacggta aactgcccac ttggcagtac atcaagtgta tcatatgcca agtacgcccc 420
ctattgacgt caatgacggt aaatggcccg cctggcatta tgcccagtac atgaccttat 480
gggactttcc tacttggcag tacatctacg tattagtcat cgctattacc atcgaggtga 540
gccccacgtt ctgcttcact ctccccatct cccccccctc cccaccccca attttgtatt 600
tatttatttt ttaattattt tgtgcagcga tgggggcggg gggggggggg gcgcgcgcca 660
ggcggggcgg ggcggggcga ggggcggggc ggggcgaggc ggagaggtgc ggcggcagcc 720
aatcagagcg gcgcgctccg aaagtttcct tttatggcga ggcggcggcg gcggcggccc 780
tataaaaagc gaagcgcgcg gcgggcggga gtcgctgcgt tgccttcgcc ccgtgccccg 840
ctccgcgccg cctcgcgccg cccgccccgg ctctgactga ccgcgttact cccacaggtg 900
agcgggcggg atgagcacgg cccggcttcg ggtgcggggc tccgtgcggg gcgtggcgcg 960
gggctcgccg tgccgggcgg ggggtggcgg caggtggggg tgccgggcgg ggcggggccg 1020
cctcgggccg gggagggctc gggggagggg cgcggcggcc ccggagcgcc ggcggctgtc 1080
gaggcgcggc gagccgcagc cattgccttt tatggtaatc gtgcgagagg gcgcagggac 1140
ttcctttgtc ccaaatctgg cggagccgaa atctgggagg cgccgccgca ccccctctag 1200
cgggcgcggg cgaagcggtg cggcgccggc aggaaggaac tgggcgggga gggccttcgt 1260
gcgtcgccgc gccgccgtcc ccttctccat ctccagcctc ggggctgccg cagggggacg 1320
gctgccttcg ggggggacgg ggcagggcgg ggttcggctt ctggcgtgtg accggcggcc 1380
tctgctaacc atgttcatgc cttcttcttt ttcctacagc tcctgggcaa cgtgctggtt 1440
attgtgctgt ctcatcattt tggcaaagaa ttgccgccac catggcctcc ctgttctctg 1500
gccgcatcct gatccgcaac aatagcgacc aggacgaact ggatacggag gctgaggtca 1560
gtcgcaggct ggagaaccgg ctggtgctgc tgttctttgg tgccggggct tgtccacagt 1620
gccaggcctt cgtgcccatc ctcaaggact tcttcgtgcg gctcacagat gagttctatg 1680
tactgcgggc ggctcagctg gccctggtgt acgtgtccca ggactccacg gaggagcagc 1740
aggacctgtt cctcaaggac atgccaaaga agtggctttt cctgcccttt gaggatgatc 1800
tgaggaggta gaataaaaga tctttatttt cattagatct gtgtgttggt tttttgtgtg 1860
atgtccctta tggtgcttct ggctctgcag ttattagcat agtgttacca tcaaccacct 1920
taacttcatt tttcttattc aatacctagg taggtagatg ctagattctg gaaataaaat 1980
atgagtctca agtggtcctt gtcctctctc ccagtcaaat tctgaatcta gttggcaaga 2040
ttctgaaatc aaggcatata atcagtaata agtgatgata gaagggtata tagaagaatt 2100
ttattatatg agagggtgaa accctcaaaa tgaaatgaaa tcagaccctt gtcttacacc 2160
ataaacaaaa ataaatttga atgggttaaa gaattaaact aagacctaaa accataaaaa 2220
tttttaaaga aatcaaaaga agaaaattct aatattcacg ttgcagccgt tttttgaatt 2280
tgatatgaga agcaaaggca acaaggaggc tgaggggtgg ggaaagggca tgggtgtttc 2340
atgaggacag agcttccgtt tcatgcaatg aaaagagttt ggagacggat ggtggtgact 2400
ggactataca cttacacacg gtagcgatgg tacactttgt attatgtata ttttaccacg 2460
atctttttaa agtgtcaaag gcaaatggcc aaatggttcc ttgtcctata gctgtagcag 2520
ccatcggctg ttagtgacaa agcccctgag tcaagatgac agcagccccc ataactccta 2580
atcggctctc ccgcgtggag tcatttagga gtagtcgcat tagagacaag tccaacatct 2640
aatcttccac cctggccagg gccccagctg gcagcgaggg tgggagactc cgggcagagc 2700
agagggcgct gacattgggg cccggcctgg cttgggtccc tctggccttt ccccaggggc 2760
cctctttcct tggggctttc ttgggccgcc actgctcccg ctcctctccc cccatcccac 2820
cccctcaccc cctcgttctt catatccttc tctagtgctc cctccacttt catccaccct 2880
tctgcaagag tgtgggacca caaatgagtt ttcacctggc ctggggacac acgtgccccc 2940
acaggtgctg agtgactttc taggacagta atctgcttta ggctaaaatg ggacttgatc 3000
ttctgttagc cctaatcatc aattagcaga gccggtgaag gtgcagaacc taccgccttt 3060
ccaggcctcc tcccacctct gccacctcca ctctccttcc tgggatgtgg gggctggcac 3120
acgtgtggcc cagggcattg gtgggattgc actgagctgg gtcattagcg taatcctgga 3180
caagggcaga cagggcgagc ggagggccag ctccggggct caggcaaggc tgggggcttc 3240
ccccagacac cccactcctc ctctgctgga cccccacttc atagggcact tcgtgttctc 3300
aaagggcttc caaatagcat ggtggccttg gatgcccagg gaagcctcag agttgcttat 3360
ctccctctag acagaagggg aatctcggtc aagagggaga ggtcgccctg ttcaaggcca 3420
cccagccagc tcatggcggt aatgggacaa ggctggccag ccatcccacc ctcagaaggg 3480
acccggtggg gcaggtgatc tcagaggagg ctcacttctg ggtctcacat tcttggatcc 3540
ggttccaggc ctcggcccta aatagtctcc ctgggctttc aagagaacca catgagaaag 3600
gaggattcgg gctctgagca gtttcaccac ccacccccca gtctgcaaat cctgacccgt 3660
gggtccacct gccccaaagg cggacgcagg acagtagaag ggaacagaga acacataaac 3720
acagagaggg ccacagcggc tcccacagtc accgccacct tcctggcggg gatgggtggg 3780
gcgtctgagt ttggttccca gcaaatccct ctgagccgcc cttgcgggct cgcctcagga 3840
gcaggggagc aagaggtggg aggaggaggt ctaagtccca ggcccaatta agagatcagg 3900
tagtgtaggg tttgggagct tttaaggtga agaggcccgg gctgatccca caggccagta 3960
taaagcgccg tgaccctcag gtgatgcgcc agggccggct gccgtcgggg acagggcttt 4020
ccatagccat ggcctccctg ttctctggcc gcatcctgat ccgcaacaat agcgaccagg 4080
acgagctgga tacggaggct gaggtcagtc gcaggctgga gaaccggctg gtgctgctgt 4140
tctttggtgc tggggcttgt ccacagtgcc aggccttcgt gcccatcctc aaggacttct 4200
tcgtgcggct cacagatgag ttctatgtac tgcgggcggc tcagctggcc ctggtgtacg 4260
tgtcccagga ctccacggag gagcagcagg acctgttcct caaggacatg ccaaagaaat 4320
ggcttttcct gccctttgag gatgatctga ggagggacct cgggcgccag ttctcagtgg 4380
agcgcctgcc ggcggtcgtg gtgctcaagc cggacgggga cgtgctcact cgcgacggcg 4440
ccgacgagat ccagcgcctg ggcaccgcct gcttcgccaa ctggcaggag gcggccgagg 4500
tgctggaccg caacttccag ctgccagagg acctggagga ccaggagcca cggagcctca 4560
ccgagtgcct gcgccgccac aagtaccgcg tggaaaaggc ggcgcgaggc gggcgcgacc 4620
ccgggggagg gggtggggag gagggcgggg ccggggggct gttctgaaac ttgtttattg 4680
cagcttataa tggttacaaa taaagcaata gcatcacaaa tttcacaaat aaagcatttt 4740
tttcactgca ttctagttgt ggtttgtcca aactcatcaa tgtatcttaa ggaaccccta 4800
gtgatggagt tggccactcc ctctctgcgc gctcgctcgc tcactgaggc cgggcgacca 4860
aaggtcgccc gacgcccggg ctttgcccgg gcggcctcag tgagcgagcg agcgcgcaga 4920
gagggagtgg ccaagcggcc gc 4942
<210> 8
<211> 4498
<212> DNA
<213> Artificial Sequence
<220>
<223> construct 7
<400> 8
gcggccgctt ggccactccc tctctgcgcg ctcgctcgct cactgaggcc gggcgaccaa 60
aggtcgcccg acgcccgggc tttgcccggg cggcctcagt gagcgagcga gcgcgcagag 120
agggagtggc caactccatc actaggggtt cctcacacaa aaaaccaaca cacagatcta 180
atgaaaataa agatctttta ttctacctcc tcagatcatc ctcaaagggc aggaaaagcc 240
acttctttgg catgtccttg aggaacaggt cctgctgctc ctccgtggag tcctgggaca 300
cgtacaccag ggccagctga gccgcccgca gtacatagaa ctcatctgtg agccgcacga 360
agaagtcctt gaggatgggc acgaaggcct ggcactgtgg acaagccccg gcaccaaaga 420
acagcagcac cagccggttc tccagcctgc gactgacctc agcctccgta tccagttcgt 480
cctggtcgct attgttgcgg atcaggatgc ggccagagaa cagggaggcc atggtggcgg 540
caattctttg ccaaaatgat gagacagcac aataaccagc acgttgccca ggagctgtag 600
gaaaaagaag aaggcatgaa catggttagc agaggccgcc ggtcacacgc cagaagccga 660
accccgccct gccccgtccc ccccgaaggc agccgtcccc ctgcggcagc cccgaggctg 720
gagatggaga aggggacggc ggcgcggcga cgcacgaagg ccctccccgc ccagttcctt 780
cctgccggcg ccgcaccgct tcgcccgcgc ccgctagagg gggtgcggcg gcgcctccca 840
gatttcggct ccgccagatt tgggacaaag gaagtccctg cgccctctcg cacgattacc 900
ataaaaggca atggctgcgg ctcgccgcgc ctcgacagcc gccggcgctc cggggccgcc 960
gcgcccctcc cccgagccct ccccggcccg aggcggcccc gccccgcccg gcacccccac 1020
ctgccgccac cccccgcccg gcacggcgag ccccgcgcca cgccccgcac ggagccccgc 1080
acccgaagcc gggccgtgct catcccgccc gctcacctgt gggagtaacg cggtcagtca 1140
gagccggggc gggcggcgcg aggcggcgcg gagcggggca cggggcgaag gcaacgcagc 1200
gactcccgcc cgccgcgcgc ttcgcttttt atagggccgc cgccgccgcc gcctcgccat 1260
aaaaggaaac tttcggagcg cgccgctctg attggctgcc gccgcacctc tccgcctcgc 1320
cccgccccgc ccctcgcccc gccccgcccc gcctggcgcg cgcccccccc ccccccgccc 1380
ccatcgctgc acaaaataat taaaaaataa ataaatacaa aattgggggt ggggaggggg 1440
gggagatggg gagagtgaag cagaacgtgg ggctcacctc gatggtaata gcgatgacta 1500
atacgtagat gtactgccaa gtaggaaagt cccataaggt catgtactgg gcataatgcc 1560
aggcgggcca tttaccgtca ttgacgtcaa tagggggcgt acttggcata tgatacactt 1620
gatgtactgc caagtgggca gtttaccgta aatactccac ccattgacgt caatggaaag 1680
tccctattgg cgttactatg ggaacatacg tcattattga cgtcaatggg cgggggtcgt 1740
tgggcggtca gccaggcggg ccatttaccg taagttatgt aacgcggaac tccatatatg 1800
ggctatgaac taatgacccc gtaattgatt actattaata actagtcaat aatcaatgtc 1860
ggaggctgag gggtggggaa agggcatggg tgtttcatga ggacagagct tccgtttcat 1920
gcaatgaaaa gagtttggag acggatggtg gtgactggac tatacactta cacacggtag 1980
cgatggtaca ctttgtatta tgtatatttt accacgatct ttttaaagtg tcaaaggcaa 2040
atggccaaat ggttccttgt cctatagctg tagcagccat cggctgttag tgacaaagcc 2100
cctgagtcaa gatgacagca gcccccataa ctcctaatcg gctctcccgc gtggagtcat 2160
ttaggagtag tcgcattaga gacaagtcca acatctaatc ttccaccctg gccagggccc 2220
cagctggcag cgagggtggg agactccggg cagagcagag ggcgctgaca ttggggcccg 2280
gcctggcttg ggtccctctg gcctttcccc aggggccctc tttccttggg gctttcttgg 2340
gccgccactg ctcccgctcc tctcccccca tcccaccccc tcaccccctc gttcttcata 2400
tccttctcta gtgctccctc cactttcatc cacccttctg caagagtgtg ggaccacaaa 2460
tgagttttca cctggcctgg ggacacacgt gcccccacag gtgctgagtg actttctagg 2520
acagtaatct gctttaggct aaaatgggac ttgatcttct gttagcccta atcatcaatt 2580
agcagagccg gtgaaggtgc agaacctacc gcctttccag gcctcctccc acctctgcca 2640
cctccactct ccttcctggg atgtgggggc tggcacacgt gtggcccagg gcattggtgg 2700
gattgcactg agctgggtca ttagcgtaat cctggacaag ggcagacagg gcgagcggag 2760
ggccagctcc ggggctcagg caaggctggg ggcttccccc agacacccca ctcctcctct 2820
gctggacccc cacttcatag ggcacttcgt gttctcaaag ggcttccaaa tagcatggtg 2880
gccttggatg cccagggaag cctcagagtt gcttatctcc ctctagacag aaggggaatc 2940
tcggtcaaga gggagaggtc gccctgttca aggccaccca gccagctcat ggcggtaatg 3000
ggacaaggct ggccagccat cccaccctca gaagggaccc ggtggggcag gtgatctcag 3060
aggaggctca cttctgggtc tcacattctt ggatccggtt ccaggcctcg gccctaaata 3120
gtctccctgg gctttcaaga gaaccacatg agaaaggagg attcgggctc tgagcagttt 3180
caccacccac cccccagtct gcaaatcctg acccgtgggt ccacctgccc caaaggcgga 3240
cgcaggacag tagaagggaa cagagaacac ataaacacag agagggccac agcggctccc 3300
acagtcaccg ccaccttcct ggcggggatg ggtggggcgt ctgagtttgg ttcccagcaa 3360
atccctctga gccgcccttg cgggctcgcc tcaggagcag gggagcaaga ggtgggagga 3420
ggaggtctaa gtcccaggcc caattaagag atcaggtagt gtagggtttg ggagctttta 3480
aggtgaagag gcccgggctg atcccacagg ccagtataaa gcgccgtgac cctcaggtga 3540
tgcgccaggg ccggctgccg tcggggacag ggctttccat agccatggcc tccctgttct 3600
ctggccgcat cctgatccgc aacaatagcg accaggacga gctggatacg gaggctgagg 3660
tcagtcgcag gctggagaac cggctggtgc tgctgttctt tggtgctggg gcttgtccac 3720
agtgccaggc cttcgtgccc atcctcaagg acttcttcgt gcggctcaca gatgagttct 3780
atgtactgcg ggcggctcag ctggccctgg tgtacgtgtc ccaggactcc acggaggagc 3840
agcaggacct gttcctcaag gacatgccaa agaaatggct tttcctgccc tttgaggatg 3900
atctgaggag ggacctcggg cgccagttct cagtggagcg cctgccggcg gtcgtggtgc 3960
tcaagccgga cggggacgtg ctcactcgcg acggcgccga cgagatccag cgcctgggca 4020
ccgcctgctt cgccaactgg caggaggcgg ccgaggtgct ggaccgcaac ttccagctgc 4080
cagaggacct ggaggaccag gagccacgga gcctcaccga gtgcctgcgc cgccacaagt 4140
accgcgtgga aaaggcggcg cgaggcgggc gcgaccccgg gggagggggt ggggaggagg 4200
gcggggccgg ggggctgttc tgaaacttgt ttattgcagc ttataatggt tacaaataaa 4260
gcaatagcat cacaaatttc acaaataaag catttttttc actgcattct agttgtggtt 4320
tgtccaaact catcaatgta tcttaaggaa cccctagtga tggagttggc cactccctct 4380
ctgcgcgctc gctcgctcac tgaggccggg cgaccaaagg tcgcccgacg cccgggcttt 4440
gcccgggcgg cctcagtgag cgagcgagcg cgcagagagg gagtggccaa gcggccgc 4498
<210> 9
<211> 5297
<212> DNA
<213> Artificial Sequence
<220>
<223> construct 8
<400> 9
gcggccgctt ggccactccc tctctgcgcg ctcgctcgct cactgaggcc gggcgaccaa 60
aggtcgcccg acgcccgggc tttgcccggg cggcctcagt gagcgagcga gcgcgcagag 120
agggagtggc caactccatc actaggggtt cctgacattg attattgact agttattaat 180
agtaatcaat tacggggtca ttagttcata gcccatatat ggagttccgc gttacataac 240
ttacggtaaa tggcccgcct ggctgaccgc ccaacgaccc ccgcccattg acgtcaataa 300
tgacgtatgt tcccatagta acgccaatag ggactttcca ttgacgtcaa tgggtggagt 360
atttacggta aactgcccac ttggcagtac atcaagtgta tcatatgcca agtacgcccc 420
ctattgacgt caatgacggt aaatggcccg cctggcatta tgcccagtac atgaccttat 480
gggactttcc tacttggcag tacatctacg tattagtcat cgctattacc atcgaggtga 540
gccccacgtt ctgcttcact ctccccatct cccccccctc cccaccccca attttgtatt 600
tatttatttt ttaattattt tgtgcagcga tgggggcggg gggggggggg gcgcgcgcca 660
ggcggggcgg ggcggggcga ggggcggggc ggggcgaggc ggagaggtgc ggcggcagcc 720
aatcagagcg gcgcgctccg aaagtttcct tttatggcga ggcggcggcg gcggcggccc 780
tataaaaagc gaagcgcgcg gcgggcggga gtcgctgcgt tgccttcgcc ccgtgccccg 840
ctccgcgccg cctcgcgccg cccgccccgg ctctgactga ccgcgttact cccacaggtg 900
agcgggcggg atgagcacgg cccggcttcg ggtgcggggc tccgtgcggg gcgtggcgcg 960
gggctcgccg tgccgggcgg ggggtggcgg caggtggggg tgccgggcgg ggcggggccg 1020
cctcgggccg gggagggctc gggggagggg cgcggcggcc ccggagcgcc ggcggctgtc 1080
gaggcgcggc gagccgcagc cattgccttt tatggtaatc gtgcgagagg gcgcagggac 1140
ttcctttgtc ccaaatctgg cggagccgaa atctgggagg cgccgccgca ccccctctag 1200
cgggcgcggg cgaagcggtg cggcgccggc aggaaggaac tgggcgggga gggccttcgt 1260
gcgtcgccgc gccgccgtcc ccttctccat ctccagcctc ggggctgccg cagggggacg 1320
gctgccttcg ggggggacgg ggcagggcgg ggttcggctt ctggcgtgtg accggcggcc 1380
tctgctaacc atgttcatgc cttcttcttt ttcctacagc tcctgggcaa cgtgctggtt 1440
attgtgctgt ctcatcattt tggcaaagaa ttgccgccac catggcctcc ctgttctctg 1500
gccgcatcct gatccgcaac aatagcgacc aggacgaact ggatacggag gctgaggtca 1560
gtcgcaggct ggagaaccgg ctggtgctgc tgttctttgg tgccggggct tgtccacagt 1620
gccaggcctt cgtgcccatc ctcaaggact tcttcgtgcg gctcacagat gagttctatg 1680
tactgcgggc ggctcagctg gccctggtgt acgtgtccca ggactccacg gaggagcagc 1740
aggacctgtt cctcaaggac atgccaaaga agtggctttt cctgcccttt gaggatgatc 1800
tgaggaggta gaataaaaga tctttatttt cattagatct gtgtgttggt tttttgtgtg 1860
atgtccctta tggtgcttct ggctctgcag ttattagcat agtgttacca tcaaccacct 1920
taacttcatt tttcttattc aatacctagg taggtagatg ctagattctg gaaataaaat 1980
atgagtctca agtggtcctt gtcctctctc ccagtcaaat tctgaatcta gttggcaaga 2040
ttctgaaatc aaggcatata atcagtaata agtgatgata gaagggtata tagaagaatt 2100
ttattatatg agagggtgaa accctcaaaa tgaaatgaaa tcagaccctt gtcttacacc 2160
ataaacaaaa ataaatttga atgggttaaa gaattaaact aagacctaaa accataaaaa 2220
tttttaaaga aatcaaaaga agaaaattct aatattcacg ttgcagccgt tttttgaatt 2280
tgatatgaga agcaaaggca acaaaaggac agggaaggga gcagtggttc acgcctgtaa 2340
tcccagcaat ttgggaggcc aaggtgggta gatcacctga gattaggagt tggagaccag 2400
cctggccaat atggtgaaac cccgtctcta ccaaaaaaac aaaaattagc tgagcctggt 2460
catgcatgcc tggaatccca acaactcggg aggctgaggc aggagaatcg cttgaaccca 2520
ggaggcggag attgcagtga gccaagattg tgccactgca ctccagcttg gttcccaata 2580
gaccccgcag gccctacagg ttgtcttccc aacttgcccc ttgctccata ccacccccct 2640
ccaccccata atattataga aggacaccta gtcagacaaa atgatgcaac ttaattttat 2700
taggacaagg ctggtgggca ctggagtggc aacttccagg gccaggagag gcactgggga 2760
ggggtcacag ggatgccacc ctcagaacag ccccccggcc ccgccctcct ccccaccccc 2820
tcccccgggg tcgcgcccgc ctcgcgccgc cttttccacg cggtacttgt ggcggcgcag 2880
gcactcggtg aggctccgtg gctcctggtc ctccaggtcc tctggcagct ggaagttgcg 2940
gtccagcacc tcggccgcct cctgccagtt ggcgaagcag gcggtgccca ggcgctggat 3000
ctcgtcggcg ccgtcgcgag tgagcacgtc cccgtccggc ttgagcacca cgaccgccgg 3060
caggcgctcc actgagaact ggcgcccgag gtccctcctc agatcatcct caaagggcag 3120
gaaaagccat ttctttggca tgtccttgag gaacaggtcc tgctgctcct ccgtggagtc 3180
ctgggacacg tacaccaggg ccagctgagc cgcccgcagt acatagaact catctgtgag 3240
ccgcacgaag aagtccttga ggatgggcac gaaggcctgg cactgtggac aagccccagc 3300
accaaagaac agcagcacca gccggttctc cagcctgcga ctgacctcag cctccgtatc 3360
cagctcgtcc tggtcgctat tgttgcggat caggatgcgg ccagagaaca gggaggccat 3420
ggctatggaa agccctgtcc ccgacggcag ccggccctgg cgcatcacct gagggtcacg 3480
gcgctttata ctggcctgtg ggatcagccc gggcctcttc accttaaaag ctcccaaacc 3540
ctacactacc tgatctctta attgggcctg ggacttagac ctcctcctcc cacctcttgc 3600
tcccctgctc ctgaggcgag cccgcaaggg cggctcagag ggatttgctg ggaaccaaac 3660
tcagacgccc cacccatccc cgccaggaag gtggcggtga ctgtgggagc cgctgtggcc 3720
ctctctgtgt ttatgtgttc tctgttccct tctactgtcc tgcgtccgcc tttggggcag 3780
gtggacccac gggtcaggat ttgcagactg gggggtgggt ggtgaaactg ctcagagccc 3840
gaatcctcct ttctcatgtg gttctcttga aagcccaggg agactattta gggccgaggc 3900
ctggaaccgg atccaagaat gtgagaccca gaagtgagcc tcctctgaga tcacctgccc 3960
caccgggtcc cttctgaggg tgggatggct ggccagcctt gtcccattac cgccatgagc 4020
tggctgggtg gccttgaaca gggcgacctc tccctcttga ccgagattcc ccttctgtct 4080
agagggagat aagcaactct gaggcttccc tgggcatcca aggccaccat gctatttgga 4140
agccctttga gaacacgaag tgccctatga agtgggggtc cagcagagga ggagtggggt 4200
gtctggggga agcccccagc cttgcctgag ccccggagct ggccctccgc tcgccctgtc 4260
tgcccttgtc caggattacg ctaatgaccc agctcagtgc aatcccacca atgccctggg 4320
ccacacgtgt gccagccccc acatcccagg aaggagagtg gaggtggcag aggtgggagg 4380
aggcctggaa aggcggtagg ttctgcacct tcaccggctc tgctaattga tgattagggc 4440
taacagaaga tcaagtccca ttttagccta aagcagatta ctgtcctaga aagtcactca 4500
gcacctgtgg gggcacgtgt gtccccaggc caggtgaaaa ctcatttgtg gtcccacact 4560
cttgcagaag ggtggatgaa agtggaggga gcactagaga aggatatgaa gaacgagggg 4620
gtgagggggt gggatggggg gagaggagcg ggagcagtgg cggcccaaga aagccccaag 4680
gaaagagggc ccctggggaa aggccagagg gacccaagcc aggccgggcc ccaatgtcag 4740
cgccctctgc tctgcccgga gtctcccacc ctcgctgcca gctggggccc tggccagggt 4800
ggaagattag atgttggact tgtctctaat gcgactactc ctaaatgact ccacgcggga 4860
gagccgatta ggagttatgg gggctgctgt catcttgact caggggcttt gtcactaaca 4920
gccgatggct gctacagcta taggacaagg aaccatttgg ccatttgcct ttgacacttt 4980
aaaaagatcg tggtaaaata tacataatac aaagtgtacc atcgctaccg tgtgtaagtg 5040
tatagtccag tcaccaccat ccgtctccaa actcttttca ttgcatgaaa cggaagctct 5100
gtcctcatga aacacccatg ccctttcccc acccctcagc ctccaggaac ccctagtgat 5160
ggagttggcc actccctctc tgcgcgctcg ctcgctcact gaggccgggc gaccaaaggt 5220
cgcccgacgc ccgggctttg cccgggcggc ctcagtgagc gagcgagcgc gcagagaggg 5280
agtggccaag cggccgc 5297
<210> 10
<211> 4360
<212> DNA
<213> Homo sapiens
<400> 10
tcaacaaatg tctcacaatt aatacatttg gcctaatgtt ttaggacaag acaaatattt 60
aatttgaaca agagatgtaa aagttaggaa ttactctagt gaaaacagat ttggatgatg 120
atggacaata ttagtgtggt gcctcaacaa agacttttgc ctcttgcata ctattatgat 180
tgcacggtaa tcttacccag ctagtgtttt cttaatgtcc tggggagcct gatcattgta 240
aattacctgt gacatctcat taatcctctt tttcctcaca aacgcataat taatggtaac 300
attgacaata atacacaaat tagctaagtg acgctttatg gtgttggttt tgattaacgt 360
caggaaccca aaaatgacgt taatgtaatg cagatcccaa aaggcagtct gcactttgac 420
cccagacata cattttgttt gcaccatcac caagattaat cctcctctgg atgaagatga 480
gacaaaactc tggccactgg cagtgtgtgc taggctgtcg gaaaacaaac cgcctcaact 540
gcatttgttt aagaaggaaa tcttaatgca cagaaaacaa cggcgtagtg tcatttccta 600
ttgtctagtt aggacaaaga taaatgagca actgtcatga ttcagatcaa ctgcttccct 660
gctaacttct attatttgct tatttatgga ctggtgttta attaaaagta tacctagata 720
tataaaccac atgataaaat aattgaaatt ccttttgctt tcactataaa tggtttttgg 780
aaatcaagac tgatttttat atgcatttca acctgcagga cctttaaatg ataaattctt 840
attaaccaca agagggtaaa caaaatcaat gcctgagaaa atatgctttg tctctgactt 900
gagtaacaaa gtaaaaacac tagaagaaat ttggataaag ttcttaactt catcagtgag 960
gcatccttgt agactctgag aaagctgata tagagacgct ttttccaaat tataaaagag 1020
acaaacactt taagtaagtc acagtagcat ctactgctgc atcatcaact tctaaattca 1080
ggcttaatca tgtgacttta atataaacat gaacagtttc ttaattacga ttttcacaaa 1140
tctgagttaa gtactgaatc tttttaacac tccaaagagg tagcatatgc taatttttta 1200
aagatgcaac cttctatttt cttcgtaaca attacttata gctgaaacat cttaatggta 1260
tacatttttt aaaaataata gtctcgtatt tgattaattt aacatctact tatttaggct 1320
atttttcaaa atgttactgc tactaaacca cagccctggc taatgatcgt attccacttc 1380
aaaaacggag taagaagaaa agccatattt tcatgctttg ttctattttt cacacaaata 1440
actatcattt atggacaaaa atatgcaaca cgtaaagtga tgtcataaaa atttgaaata 1500
aatccaccaa aattggaaag caaagatcac cgaaattatg aaacattgtg ggtatatttg 1560
ataaaaagaa gatactattt ttgattaaaa aaagagaata tcttaaaaag aagattttgg 1620
ttgctgtggg tatgtatttt caattgtgag gcctctaatc cacctctccc ccaaaataag 1680
aaaacagact gccttacaac tgcttgtcat agcagtttaa ttttgaaaaa tgcctcatct 1740
gtccctgctt gcaatatatt gtcttacgac tacgtttacc ttttttattt tttggggggg 1800
ggttattgaa agttacaagg agcaaaataa tgtttttaga gaattttttt cttctcttgt 1860
ttaaatatta ttttaaaatc aaaagcagct catttttaaa tcgacatatt aagtgttagc 1920
tgcaccaact ttcaccagca cacaaaccca ttgtaaagca aactggaatt taaggggcaa 1980
tggggagtcc tacagaggtc atattttcac tctgcctaac taaaccataa atcaagatta 2040
caacaataaa ttatttttta ttattttggc aggaataagt atagccttga attttgaaag 2100
atatttgggc ttaattcata tgttaaatag gtcgggataa accaatgcta gaagaaattg 2160
aaactggccc aatattatac agaaacccaa attaggcact caccaccaaa ctaattagta 2220
attgataaat ttacaatagt aatgtaattt ctttacactg caaagccaaa gaaataggat 2280
aattgaaagc ttcaaatcta aaaaaaaaaa aattgacaat cttttaatca aaggcattgt 2340
ttacaacgtg gcttttaggt agctgcagta acatctttaa ctggttaaaa acactcatca 2400
agctataaaa ctactttctt agatgtctat agcaaactgt ttgaaacctc ccaaagtgcc 2460
ttaatttata ttttttcagc agctacaatg aatgttactt tcttccagtc caaatgtatc 2520
attttcactt ttcaacttat tcaagttcat agagagcaac ctatgaagcc acaattttat 2580
agaaatctat ttttcaggtt taaatgtggt accctgactt ttcataagct ccaatagttg 2640
tgccaagtta cttttttgtt gttgttctaa ggaaagattt tatgcaaata aagagactgc 2700
tctgtgggaa agcatgtttt cttaagtatt taatcggaca tttccacacc acaacacttt 2760
gtagacatgt ttttgctttg aaaacataat cttatcaggg gtggttggtg tacaattctt 2820
gtctgttttc ttacctttga atttgagctc tatttataag gctcaactaa atgatgtctg 2880
cagctaaggc atttccttac tagggagttt tacacgaaca caattaatat gaaagcacac 2940
aacgcattga acagggtgtc aatttaggtt tccggtacaa tgtaacctta tcgaagtgtt 3000
cccgtttaca tagaagaaaa caaatatgat aaagcggtta aatatgtatc tgtcttagat 3060
ttctaacatt ttcctctcga tatatctttt cggaataaac aaagggaagt gaattcttca 3120
ttccttattt gtacaaacaa gtgaaattgg gtccccttca cgatggaagg cactggcctt 3180
tctcctcaca tggaacaaac tgctagagaa acttggttta cacaaaatgg aaacatttaa 3240
tccttgcatc tatatttcaa aatagtacat ggtttttcca taaatctatg tgtgatgaca 3300
tatttcgtaa cattacataa ggctttccat gcatttttat tcatgggaga atggcttgca 3360
gaaaatcaca acattgtact atgcttctcc agcaagttaa ttttcacttt actgcgaata 3420
tacagtttat ggaaaaataa tagttattta agtgtagcgt acttacctgt tgctgtggga 3480
aaattcctac cattaaaaat gtgctttcac ttcagttatt attataatgt aggctatacc 3540
aatgcctgat gatttttata aacagaacct ataaatctgc attttggttc agggctgtac 3600
tatttagaca aatgaaaatg aagcagcatg acatgaagtc caaaggaacg ttcttataca 3660
tgcctcaact ttggtttttt ggtaactgcc ctttggagac tatcctttat taaggatctt 3720
aatgagggtt ctgcctgtat ttttctccca agaatgtcaa ataaggttcg aaagcaaatg 3780
taaactgtaa tacaagtgac acacactaaa aatagcccta taaatctgtt cattttgttt 3840
agatagtctc cagagttgta aaaagtagga ctgttcagct ttattatttg ttttggaaaa 3900
cctaattctg tagagaatag gccactgata atgctatatt actttagagg agatttatta 3960
agactgtctc tagatttaat ttttttaaaa taaagaaact ctttcctgtt tttattttcc 4020
aaataatcta caagataatt aactgaatat aatctataat attaaataaa ttttcccatt 4080
tactcattag aattaagatt ttgaaaggca catttatcta aactaaaatt aattaaaatt 4140
tcaaatagaa ttctcattcc tattaacctg tcaaatatgt tgcgttcaat gtttccagta 4200
acagaacaac aatatttatt atctaacgta ccataagttt ttaaaaataa ctccaggaga 4260
acatttttgg aacacttaca atctgaatag acaactaaaa aaatcagaca tttctgtgtg 4320
aaaaatagct attgtaaatt aaaatggttg agggagaata 4360
<210> 11
<211> 330
<212> DNA
<213> Homo sapiens
<400> 11
atggcctcct tgttctccgg ccgaatcctg atccgaaaca atagtgacca ggatgagctg 60
gatacagaag ctgaggtcag tcgcagactg gagaacaggc tggtccttct gttctttggt 120
gctggggctt gtcctcagtg ccaggccttc gtgcccatcc tcaaggactt ctttgtgcgg 180
ctcacggatg agttctatgt actgcgggca gctcaactgg ctctagtata tgtgtcacag 240
gactccactg aggagcagca ggacctcttc ctgaaggaca tgccaaagaa atggcttttc 300
ctgccctttg aggatgatct gaggaggtag 330
<210> 12
<211> 330
<212> DNA
<213> Artificial Sequence
<220>
<223> codon-optimized
<400> 12
atggccagcc tcttctccgg acgcatcctg attcgcaaca attccgacca agacgaactg 60
gataccgagg ccgaagtctc gcggagattg gagaacaggc ttgtgctgct gttctttggc 120
gcgggagcgt gtcctcagtg ccaggctttc gtgccaatcc tgaaggattt cttcgtgcgg 180
ctgactgacg aattctacgt cctccgggcc gcccagctgg cactggtgta cgtgtcccaa 240
gactcaaccg aggaacagca ggatctgttc ctcaaggaca tgcccaaaaa gtggctgttc 300
ctgccgtttg aggacgactt gcggcgctag 330
<210> 13
<211> 639
<212> DNA
<213> Artificial Sequence
<220>
<223> codon-optimized
<400> 13
atggcctcac tgttctccgg gcgcatcctc atccgaaaca acagcgatca ggacgaattg 60
gacaccgagg ctgaagtctc ccgccggctg gaaaacaggc tcgtgctcct gttcttcggt 120
gccggagcgt gcccgcagtg ccaagccttc gtcccaattc ttaaggactt ctttgtgcgc 180
ctcactgatg agttttacgt gctccgggca gcgcagctgg ccttggtgta tgtgtcgcaa 240
gattccactg aggaacaaca ggacctgttc ctgaaagaca tgcctaagaa gtggcttttc 300
ctgcccttcg aggacgacct gagaagggac ctgggacgcc agttcagcgt ggaacggctg 360
ccggccgtcg tggtgctgaa gcccgacggg gacgtgctta cccgggatgg cgctgacgaa 420
atccagaggc tgggcaccgc ctgtttcgca aattggcagg aggccgccga agtgctcgac 480
cggaacttcc agctgcccga ggatctggag gaccaggaac ctcggtccct gaccgagtgc 540
ctcagacgcc acaagtaccg cgtggaaaag gccgcgagag gaggacggga cccgggtggc 600
gggggaggcg aagagggcgg agccggtggc ctgttctga 639
<210> 14
<211> 4934
<212> DNA
<213> Artificial Sequence
<220>
<223> construct 11
<400> 14
ttggccactc cctctctgcg cgctcgctcg ctcactgagg ccgggcgacc aaaggtcgcc 60
cgacgcccgg gctttgcccg ggcggcctca gtgagcgagc gagcgcgcag agagggagtg 120
gccaactcca tcactagggg ttcctgacat tgattattga ctagttatta atagtaatca 180
attacggggt cattagttca tagcccatat atggagttcc gcgttacata acttacggta 240
aatggcccgc ctggctgacc gcccaacgac ccccgcccat tgacgtcaat aatgacgtat 300
gttcccatag taacgccaat agggactttc cattgacgtc aatgggtgga gtatttacgg 360
taaactgccc acttggcagt acatcaagtg tatcatatgc caagtacgcc ccctattgac 420
gtcaatgacg gtaaatggcc cgcctggcat tatgcccagt acatgacctt atgggacttt 480
cctacttggc agtacatcta cgtattagtc atcgctatta ccatcgaggt gagccccacg 540
ttctgcttca ctctccccat ctcccccccc tccccacccc caattttgta tttatttatt 600
ttttaattat tttgtgcagc gatgggggcg gggggggggg gggcgcgcgc caggcggggc 660
ggggcggggc gaggggcggg gcggggcgag gcggagaggt gcggcggcag ccaatcagag 720
cggcgcgctc cgaaagtttc cttttatggc gaggcggcgg cggcggcggc cctataaaaa 780
gcgaagcgcg cggcgggcgg gagtcgctgc gttgccttcg ccccgtgccc cgctccgcgc 840
cgcctcgcgc cgcccgcccc ggctctgact gaccgcgtta ctcccacagg tgagcgggcg 900
ggatgagcac ggcccggctt cgggtgcggg gctccgtgcg gggcgtggcg cggggctcgc 960
cgtgccgggc ggggggtggc ggcaggtggg ggtgccgggc ggggcggggc cgcctcgggc 1020
cggggagggc tcgggggagg ggcgcggcgg ccccggagcg ccggcggctg tcgaggcgcg 1080
gcgagccgca gccattgcct tttatggtaa tcgtgcgaga gggcgcaggg acttcctttg 1140
tcccaaatct ggcggagccg aaatctggga ggcgccgccg caccccctct agcgggcgcg 1200
ggcgaagcgg tgcggcgccg gcaggaagga actgggcggg gagggccttc gtgcgtcgcc 1260
gcgccgccgt ccccttctcc atctccagcc tcggggctgc cgcaggggga cggctgcctt 1320
cgggggggac ggggcagggc ggggttcggc ttctggcgtg tgaccggcgg cctctgctaa 1380
ccatgttcat gccttcttct ttttcctaca gctcctgggc aacgtgctgg ttattgtgct 1440
gtctcatcat tttggcaaag aattgccgcc accatggcct ccttgttctc cggccgaatc 1500
ctgatccgaa acaatagtga ccaggatgag ctggatacag aagctgaggt cagtcgcaga 1560
ctggagaaca ggctggtcct tctgttcttt ggtgctgggg cttgtcctca gtgccaggcc 1620
ttcgtgccca tcctcaagga cttctttgtg cggctcacgg atgagttcta tgtactgcgg 1680
gcagctcaac tggctctagt atatgtgtca caggactcca ctgaggagca gcaggacctc 1740
ttcctgaagg acatgccaaa gaaatggctt ttcctgccct ttgaggatga tctgaggagg 1800
tagaataaaa gatctttatt ttcattagat ctgtgtgttg gttttttgtg tgatgtccct 1860
tatggtgctt ctggctctgc agttattagc atagtgttac catcaaccac cttaacttca 1920
tttttcttat tcaataccta ggtaggtaga tgctagattc tggaaataaa atatgagtct 1980
caagtggtcc ttgtcctctc tcccagtcaa attctgaatc tagttggcaa gattctgaaa 2040
tcaaggcata taatcagtaa taagtgatga tagaagggta tatagaagaa ttttattata 2100
tgagagggtg aaaccctcaa aatgaaatga aatcagaccc ttgtcttaca ccataaacaa 2160
aaataaattt gaatgggtta aagaattaaa ctaagaccta aaaccataaa aatttttaaa 2220
gaaatcaaaa gaagaaaatt ctaatattca cgttgcagcc gttttttgaa tttgatatga 2280
gaagcaaagg caacaaggag gctgaggggt ggggaaaggg catgggtgtt tcatgaggac 2340
agagcttccg tttcatgcaa tgaaaagagt ttggagacgg atggtggtga ctggactata 2400
cacttacaca cggtagcgat ggtacacttt gtattatgta tattttacca cgatcttttt 2460
aaagtgtcaa aggcaaatgg ccaaatggtt ccttgtccta tagctgtagc agccatcggc 2520
tgttagtgac aaagcccctg agtcaagatg acagcagccc ccataactcc taatcggctc 2580
tcccgcgtgg agtcatttag gagtagtcgc attagagaca agtccaacat ctaatcttcc 2640
accctggcca gggccccagc tggcagcgag ggtgggagac tccgggcaga gcagagggcg 2700
ctgacattgg ggcccggcct ggcttgggtc cctctggcct ttccccaggg gccctctttc 2760
cttggggctt tcttgggccg ccactgctcc cgctcctctc cccccatccc accccctcac 2820
cccctcgttc ttcatatcct tctctagtgc tccctccact ttcatccacc cttctgcaag 2880
agtgtgggac cacaaatgag ttttcacctg gcctggggac acacgtgccc ccacaggtgc 2940
tgagtgactt tctaggacag taatctgctt taggctaaaa tgggacttga tcttctgtta 3000
gccctaatca tcaattagca gagccggtga aggtgcagaa cctaccgcct ttccaggcct 3060
cctcccacct ctgccacctc cactctcctt cctgggatgt gggggctggc acacgtgtgg 3120
cccagggcat tggtgggatt gcactgagct gggtcattag cgtaatcctg gacaagggca 3180
gacagggcga gcggagggcc agctccgggg ctcaggcaag gctgggggct tcccccagac 3240
accccactcc tcctctgctg gacccccact tcatagggca cttcgtgttc tcaaagggct 3300
tccaaatagc atggtggcct tggatgccca gggaagcctc agagttgctt atctccctct 3360
agacagaagg ggaatctcgg tcaagaggga gaggtcgccc tgttcaaggc cacccagcca 3420
gctcatggcg gtaatgggac aaggctggcc agccatccca ccctcagaag ggacccggtg 3480
gggcaggtga tctcagagga ggctcacttc tgggtctcac attcttggat ccggttccag 3540
gcctcggccc taaatagtct ccctgggctt tcaagagaac cacatgagaa aggaggattc 3600
gggctctgag cagtttcacc acccaccccc cagtctgcaa atcctgaccc gtgggtccac 3660
ctgccccaaa ggcggacgca ggacagtaga agggaacaga gaacacataa acacagagag 3720
ggccacagcg gctcccacag tcaccgccac cttcctggcg gggatgggtg gggcgtctga 3780
gtttggttcc cagcaaatcc ctctgagccg cccttgcggg ctcgcctcag gagcagggga 3840
gcaagaggtg ggaggaggag gtctaagtcc caggcccaat taagagatca ggtagtgtag 3900
ggtttgggag cttttaaggt gaagaggccc gggctgatcc cacaggccag tataaagcgc 3960
cgtgaccctc aggtgatgcg ccagggccgg ctgccgtcgg ggacagggct ttccatagcc 4020
atggcctccc tgttctctgg ccgcatcctg atccgcaaca atagcgacca ggacgagctg 4080
gatacggagg ctgaggtcag tcgcaggctg gagaaccggc tggtgctgct gttctttggt 4140
gctggggctt gtccacagtg ccaggccttc gtgcccatcc tcaaggactt cttcgtgcgg 4200
ctcacagatg agttctatgt actgcgggcg gctcagctgg ccctggtgta cgtgtcccag 4260
gactccacgg aggagcagca ggacctgttc ctcaaggaca tgccaaagaa atggcttttc 4320
ctgccctttg aggatgatct gaggagggac ctcgggcgcc agttctcagt ggagcgcctg 4380
ccggcggtcg tggtgctcaa gccggacggg gacgtgctca ctcgcgacgg cgccgacgag 4440
atccagcgcc tgggcaccgc ctgcttcgcc aactggcagg aggcggccga ggtgctggac 4500
cgcaacttcc agctgccaga ggacctggag gaccaggagc cacggagcct caccgagtgc 4560
ctgcgccgcc acaagtaccg cgtggaaaag gcggcgcgag gcgggcgcga ccccggggga 4620
gggggtgggg aggagggcgg ggccgggggg ctgttctgaa acttgtttat tgcagcttat 4680
aatggttaca aataaagcaa tagcatcaca aatttcacaa ataaagcatt tttttcactg 4740
cattctagtt gtggtttgtc caaactcatc aatgtatctt aaggaacccc tagtgatgga 4800
gttggccact ccctctctgc gcgctcgctc gctcactgag gccgggcgac caaaggtcgc 4860
ccgacgcccg ggctttgccc gggcggcctc agtgagcgag cgagcgcgca gagagggagt 4920
ggccaagcgg ccgc 4934
<210> 15
<211> 12646
<212> DNA
<213> Artificial Sequence
<220>
<223> CT35
<400> 15
tagaaaaact catcgagcat caaatgaaat tgcaatttat tcatatcagg attatcaata 60
ccatattttt gaaaaagccg tttctgtaat gaaggagaaa actcaccgag gcagttccat 120
aggatggcaa gatcctggta tcggtctgcg attccgactc gtccaacatc aatacaacct 180
attaatttcc cctcgtcaaa aataaggtta tcaagtgaga aatcaccatg agtgacgact 240
gaatccggtg agaatggcaa aagtttatgc atttctttcc agacttgttc aacaggccag 300
ccattacgct cgtcatcaaa atcactcgca tcaaccaaac cgttattcat tcgtgattgc 360
gcctgagcga ggcgaaatac gcgatcgctg ttaaaaggac aattacaaac aggaatcgag 420
tgcaaccggc gcaggaacac tgccagcgca tcaacaatat tttcacctga atcaggatat 480
tcttctaata cctggaacgc tgtttttccg gggatcgcag tggtgagtaa ccatgcatca 540
tcaggagtac ggataaaatg cttgatggtc ggaagtggca taaattccgt cagccagttt 600
agtctgacca tctcatctgt aacatcattg gcaacgctac ctttgccatg tttcagaaac 660
aactctggcg catcgggctt cccatacaag cgatagattg tcgcacctga ttgcccgaca 720
ttatcgcgag cccatttata cccatataaa tcagcatcca tgttggaatt taatcgcggc 780
ctcgacgttt cccgttgaat atggctcata ttcttccttt ttcaatatta ttgaagcatt 840
tatcagggtt attgtctcat gagcggatac atatttgaat gtatttagaa aaataaacaa 900
ataggggtca gtgttacaac caattaacca attctgaaca ttatcgcgag cccatttata 960
cctgaatatg gctcataaca ccccttgttt gcctggcggc agtagcgcgg tggtcccacc 1020
tgaccccatg ccgaactcag aagtgaaacg ccgtagcgcc gatggtagtg tggggactcc 1080
ccatgcgaga gtagggaact gccaggcatc aaataaaacg aaaggctcag tcgaaagact 1140
gggcctttcg cccgggctaa ttagggggtg tcgcccttat tcgactctat agtgaagttc 1200
ctattctcta gaaagtatag gaacttctga agtggggtcg acttaattaa ggctgcgcgc 1260
tcgctcgctc actgaggccg cccgggcaaa gcccgggcgt cgggcgacct ttggtcgccc 1320
ggcctcagtg agcgagcgag cgcgcagaga gggagtggcc aactccatca ctaggggttc 1380
cttgtagtta atgattaacc cgccatgcta cttatctacg tagcaagcta gctagttatt 1440
aatagtaatc aattacgggg tcattagttc atagcccata tatggagttc cgcgttacat 1500
aacttacggt aaatggcccg cctggctgac cgcccaacga cccccgccca ttgacgtcaa 1560
taatgacgta tgttcccata gtaacgccaa tagggacttt ccattgacgt caatgggtgg 1620
agtatttacg gtaaactgcc cacttggcag tacatcaagt gtatcatatg ccaagtacgc 1680
cccctattga cgtcaatgac ggtaaatggc ccgcctggca ttatgcccag tacatgacct 1740
tatgggactt tcctacttgg cagtacatct acgtattagt catcgctatt aacatggtcg 1800
aggtgagccc cacgttctgc ttcactctcc ccatctcccc cccctcccca cccccaattt 1860
tgtatttatt tattttttaa ttattttgtg cagcgatggg ggcggggggg gggggggggc 1920
gcgcgccagg cggggcgggg cggggcgagg ggcggggcgg ggcgaggcgg agaggtgcgg 1980
cggcagccaa tcagagcggc gcgctccgaa agtttccttt tatggcgagg cggcggcggc 2040
ggcggcccta taaaaagcga agcgcgcggc gggcgggagt cgctgcgcgc tgccttcgcc 2100
ccgtgccccg ctccgccgcc gcctcgcgcc gcccgccccg gctctgactg accgcgttac 2160
tcccacaggt gagcgggcgg gagcacggcc cggcttcggg tgcggggctc cgtacggggc 2220
gtggcgcggg gctcgccgtg ccgggcgggg ggtggcggca ggtgggggtg ccgggcgggg 2280
cggggccgcc tcgggccggg gagggctcgg gggaggggcg cggcggcccc cggagcgccg 2340
gcggctgtcg aggcgcggcg agccgcagcc attgcctttt atggtaatcg tgcgagaggg 2400
cgcagggact tcctttgtcc caaatctgtg cggagccgaa atctgggagg cgccgccgca 2460
ccccctctag cgggcgcggg gcgaagcggt gcggcgccgg caggaaggaa atgggcgggg 2520
agggccttcg tgcgtcgccg cgccgccgtc cccttctccc tctccagcct cggggctgtc 2580
cgcgggggga cggctgcctt cgggggggac ggggcagggc ggggttcggc ttctggcgtg 2640
tgaccggcgg ctctagacaa ttgtactaac cttcttctct ttcctctcct gacaggttgg 2700
tgtacactag cggccgccac catggccagc ctcttctccg gacgcatcct gattcgcaac 2760
aattccgacc aagacgaact ggataccgag gccgaagtct cgcggagatt ggagaacagg 2820
cttgtgctgc tgttctttgg cgcgggagcg tgtcctcagt gccaggcttt cgtgccaatc 2880
ctgaaggatt tcttcgtgcg gctgactgac gaattctacg tcctccgggc cgcccagctg 2940
gcactggtgt acgtgtccca agactcaacc gaggaacagc aggatctgtt cctcaaggac 3000
atgcccaaaa agtggctgtt cctgccgttt gaggacgact tgcggcgcta gtgatcagcc 3060
tcgactgtgc cttctagttg ccagccatct gttgtttgcc cctcccccgt gccttccttg 3120
accctggaag gtgccactcc cactgtcctt tcctaataaa atgaggaaat tgcatcgcat 3180
tgtctgagta ggtgtcattc tattctgggg ggtggggtgg ggcaggacag caagggggag 3240
gattgggaag acaatagcag gcatgctggg gaggatccaa tttattctaa atgcataata 3300
aatactgata acatcttata gtttgtatta tattttgtat tatcgttgac atgtataatt 3360
ttgatatcaa aaactgattt tccctttatt attttcgaga tttattttct taattctctt 3420
taacaaacta gaaatattgt atatacaaaa aatcataaat aatagatgaa tagtttaatt 3480
ataggtgttc atcaatcgaa aaagcaacgt atcttattta aagtgcgttg cttttttctc 3540
atttataagg ttaaataatt ctcatatatc aagcaaagtg acaggcgccc ttaaatattc 3600
tgacaaatgc tctttcccta aactcccccc ataaaaaaac ccgccgaagc gggtttttac 3660
gttatttgcg gattaacgat tactcgttat cagaaccgcc caggaagctt tagttattaa 3720
tagtaatcaa ttacggggtc attagttcat agcccatata tggagttccg cgttacataa 3780
cttacggtaa atggcccgcc tggctgaccg cccaacgacc cccgcccatt gacgtcaata 3840
atgacgtatg ttcccatagt aacgccaata gggactttcc attgacgtca atgggtggag 3900
tatttacggt aaactgccca cttggcagta catcaagtgt atcatatgcc aagtacgccc 3960
cctattgacg tcaatgacgg taaatggccc gcctggcatt atgcccagta catgacctta 4020
tgggactttc ctacttggca gtacatctac gtattagtca tcgctattaa catggtcgag 4080
gtgagcccca cgttctgctt cactctcccc atctcccccc cctccccacc cccaattttg 4140
tatttattta ttttttaatt attttgtgca gcgatggggg cggggggggg gggggggcgc 4200
gcgccaggcg gggcggggcg gggcgagggg cggggcgggg cgaggcggag aggtgcggcg 4260
gcagccaatc agagcggcgc gctccgaaag tttcctttta tggcgaggcg gcggcggcgg 4320
cggccctata aaaagcgaag cgcgcggcgg gcggggagtc gctgcgacgc tgccttcgcc 4380
ccgtgccccg ctccgccgcc gcctcgcgcc gcccgccccg gctctgactg accgcgttac 4440
tcccacaggt gagcgggcgg gatgagcacg gcccggcttc gggtgcgggg ctccgtacgg 4500
ggcgtggcgc ggggctcgcc gtgccgggcg gggggtggcg gcaggtgggg gtgccgggcg 4560
gggcggggcc gcctcgggcc ggggagggct cgggggaggg gcgcggcggc ccccggagcg 4620
ccggcggctg tcgaggcgcg gcgagccgca gccattgcct tttatggtaa tcgtgcgaga 4680
gggcgcaggg acttcctttg tcccaaatct gtgcggagcc gaaatctggg aggcgccgcc 4740
gcaccccctc tagcgggcgc ggggcgaagc ggtgcggcgc cggcaggaag gaaatgggcg 4800
gggagggcct tcgtgcgtcg ccgcgccgcc gtccccttct ccctctccag cctcggggct 4860
gtccgcgggg ggacggctgc cttcgggggg gacggggcag ggcggggttc ggcttctggc 4920
gtgtgaccgg cggctctaga caattgtact aaccttcttc tctttcctct cctgacaggt 4980
tggtgtacac taggccatac aggccgccac catggcctca ctgttctccg ggcgcatcct 5040
catccgaaac aacagcgatc aggacgaatt ggacaccgag gctgaagtct cccgccggct 5100
ggaaaacagg ctcgtgctcc tgttcttcgg tgccggagcg tgcccgcagt gccaagcctt 5160
cgtcccaatt cttaaggact tctttgtgcg cctcactgat gagttttacg tgctccgggc 5220
agcgcagctg gccttggtgt atgtgtcgca agattccact gaggaacaac aggacctgtt 5280
cctgaaagac atgcctaaga agtggctttt cctgcccttc gaggacgacc tgagaaggga 5340
cctgggacgc cagttcagcg tggaacggct gccggccgtc gtggtgctga agcccgacgg 5400
ggacgtgctt acccgggatg gcgctgacga aatccagagg ctgggcaccg cctgtttcgc 5460
aaattggcag gaggccgccg aagtgctcga ccggaacttc cagctgcccg aggatctgga 5520
ggaccaggaa cctcggtccc tgaccgagtg cctcagacgc cacaagtacc gcgtggaaaa 5580
ggccgcgaga ggaggacggg acccgggtgg cgggggaggc gaagagggcg gagccggtgg 5640
cctgttctga tagatctgcc tcgactgtgc cttctagttg ccagccatct gttgtttgcc 5700
cctcccccgt gccttccttg accctggaag gtgccactcc cactgtcctt tcctaataaa 5760
atgaggaaat tgcatcgcat tgtctgagta ggtgtcattc tattctgggg ggtggggtgg 5820
ggcaggacag caagggggag gattgggaag acaatagcag gcatgctggg gactcgagtt 5880
ctacgtagat aagtagcatg gcgggttaat cattaactac aaggaacccc tagtgatgga 5940
gttggccact ccctctctgc gcgctcgctc gctcactgag gccgggcgac caaaggtcgc 6000
ccgacgcccg ggctttgccc gggcggcctc agtgagcgag cgagcgcgca gccttaatta 6060
acctaaggaa aatgaagtga agttcctata ctttctagag aataggaact tctatagtga 6120
gtcgaataag ggcgacacaa aatttattct aaatgcataa taaatactga taacatctta 6180
tagtttgtat tatattttgt attatcgttg acatgtataa ttttgatatc aaaaactgat 6240
tttcccttta ttattttcga gatttatttt cttaattctc tttaacaaac tagaaatatt 6300
gtatatacaa aaaatcataa ataatagatg aatagtttaa ttataggtgt tcatcaatcg 6360
aaaaagcaac gtatcttatt taaagtgcgt tgcttttttc tcatttataa ggttaaataa 6420
ttctcatata tcaagcaaag tgacaggcgc ccttaaatat tctgacaaat gctctttccc 6480
taaactcccc ccataaaaaa acccgccgaa gcgggttttt acgttatttg cggattaacg 6540
attactcgtt atcagaaccg cccagggggc ccgagcttaa cctttttatt tgggggagag 6600
ggaagtcatg aaaaaactaa cctttgaaat tcgatctcca gcacatcagc aaaacgctat 6660
tcacgcagta cagcaaatcc ttccagaccc aaccaaacca atcgtagtaa ccattcagga 6720
acgcaaccgc agcttagacc aaaacaggaa gctatgggcc tgcttaggtg acgtctctcg 6780
tcaggttgaa tggcatggtc gctggctgga tgcagaaagc tggaagtgtg tgtttaccgc 6840
agcattaaag cagcaggatg ttgttcctaa ccttgccggg aatggctttg tggtaatagg 6900
ccagtcaacc agcaggatgc gtgtaggcga atttgcggag ctattagagc ttatacaggc 6960
attcggtaca gagcgtggcg ttaagtggtc agacgaagcg agactggctc tggagtggaa 7020
agcgagatgg ggagacaggg ctgcatgata aatgtcgtta gtttctccgg tggcaggacg 7080
tcagcatatt tgctctggct aatggagcaa aagcgacggg caggtaaaga cgtgcattac 7140
gttttcatgg atacaggttg tgaacatcca atgacatatc ggtttgtcag ggaagttgtg 7200
aagttctggg atataccgct caccgtattg caggttgata tcaacccgga gcttggacag 7260
ccaaatggtt atacggtatg ggaaccaaag gatattcaga cgcgaatgcc tgttctgaag 7320
ccatttatcg atatggtaaa gaaatatggc actccatacg tcggcggcgc gttctgcact 7380
gacagattaa aactcgttcc cttcaccaaa tactgtgatg accatttcgg gcgagggaat 7440
tacaccacgt ggattggcat cagagctgat gaaccgaagc ggctaaagcc aaagcctgga 7500
atcagatatc ttgctgaact gtcagacttt gagaaggaag atatcctcgc atggtggaag 7560
caacaaccat tcgatttgca aataccggaa catctcggta actgcatatt ctgcattaaa 7620
aaatcaacgc aaaaaatcgg acttgcctgc aaagatgagg agggattgca gcgtgttttt 7680
aatgaggtca tcacgggatc ccatgtgcgt gacggacatc gggaaacgcc aaaggagatt 7740
atgtaccgag gaagaatgtc gctggacggt atcgcgaaaa tgtattcaga aaatgattat 7800
caagccctgt atcaggacat ggtacgagct aaaagattcg ataccggctc ttgttctgag 7860
tcatgcgaaa tatttggagg gcagcttgat ttcgacttcg ggagggaagc tgcatgatgc 7920
gatgttatcg gtgcggtgaa tgcaaagaag ataaccgctt ccgaccaaat caaccttact 7980
ggaatcgatg gtgtctccgg tgtgaaagaa caccaacagg ggtgttacca ctaccgcagg 8040
aaaaggagga cgtgtggcga gacagcgacg aagtatcacc gacataatct gcgaaaactg 8100
caaatacctt ccaacgaaac gcaccagaaa taaacccaag ccaatcccaa aagaatctga 8160
cgtaaaaacc ttcaactaca cggctcacct gtgggatatc cggtggctaa gacgtcgtgc 8220
gaggaaaaca aggtgattga ccaaaatcga agttacgaac aagaaagcgt cgagcgagct 8280
ttaacgtgcg ctaactgcgg tcagaagctg catgtgctgg aagttcacgt gtgtgagcac 8340
tgctgcgcag aactgatgag cgatccgaat agctcgatgc acgaggaaga agatgatggc 8400
taaaccagcg cgaagacgat gtaaaaacga tgaatgccgg gaatggtttc accctgcatt 8460
cgctaatcag tggtggtgct ctccagagtg tggaaccaag atagcactcg aacgacgaag 8520
taaagaacgc gaaaaagcgg aaaaagcagc agagaagaaa cgacgacgag aggagcagaa 8580
acagaaagat aaacttaaga ttcgaaaact cgccttaaag ccccgcagtt actggattaa 8640
acaagcccaa caagccgtaa acgccttcat cagagaaaga gaccgcgact taccatgtat 8700
ctcgtgcgga acgctcacgt ctgctcagtg ggatgccgga cattaccgga caactgctgc 8760
ggcacctcaa ctccgattta atgaacgcaa tattcacaag caatgcgtgg tgtgcaacca 8820
gcacaaaagc ggaaatctcg ttccgtatcg cgtcgaactg attagccgca tcgggcagga 8880
agcagtagac gaaatcgaat caaaccataa ccgccatcgc tggactatcg aagagtgcaa 8940
ggcgatcaag gcagagtacc aacagaaact caaagacctg cgaaatagca gaagtgaggc 9000
cgcatgacgt tctcagtaaa aaccattcca gacatgctcg ttgaaacata cggaaatcag 9060
acagaagtag cacgcagact gaaatgtagt cgcggtacgg tcagaaaata cgttgatgat 9120
aaagacggga aaatgcacgc catcgtcaac gacgttctca tggttcatcg cggatggagt 9180
gaaagagatg cgctattacg aaaaaattga tggcagcaaa taccgaaata tttgggtagt 9240
tggcgatctg cacggatgct acacgaacct gatgaacaaa ctggatacga ttggattcga 9300
caacaaaaaa gacctgctta tctcggtggg cgatttggtt gatcgtggtg cagagaacgt 9360
tgaatgcctg gaattaatca cattcccctg gttcagagct gtacgtggaa accatgagca 9420
aatgatgatt gatggcttat cagagcgtgg aaacgttaat cactggctgc ttaatggcgg 9480
tggctggttc tttaatctcg attacgacaa agaaattctg gctaaagctc ttgcccataa 9540
agcagatgaa cttccgttaa tcatcgaact ggtgagcaaa gataaaaaat atgttatctg 9600
ccacgccgat tatccctttg acgaatacga gtttggaaag ccagttgatc atcagcaggt 9660
aatctggaac cgcgaacgaa tcagcaactc acaaaacggg atcgtgaaag aaatcaaagg 9720
cgcggacacg ttcatctttg gtcatacgcc agcagtgaaa ccactcaagt ttgccaacca 9780
aatgtatatc gataccggcg cagtgttctg cggaaaccta acattgattc aggtacaggg 9840
agaaggcgca tgagactcga aagcgtagct aaatttcatt cgccaaaaag cccgatgatg 9900
agcgactcac cacgggccac ggcttctgac tctctttccg gtactgatgt gatggctgct 9960
atggggatgg cgcaatcaca agccggattc ggtatggctg cattctgcgg taagcacgaa 10020
ctcagccaga acgacaaaca aaaggctatc aactatctga tgcaatttgc acacaaggta 10080
tcggggaaat accgtggtgt ggcaaagctt gaaggaaata ctaaggcaaa ggtactgcaa 10140
gtgctcgcaa cattcgctta tgcggattat tgccgtagtg ccgcgacgcc gggggcaaga 10200
tgcagagatt gccatggtac aggccgtgcg gttgatattg ccaaaacaga gctgtggggg 10260
agagttgtcg agaaagagtg cggaagatgc aaaggcgtcg gctattcaag gatgccagca 10320
agcgcagcat atcgcgctgt gacgatgcta atcccaaacc ttacccaacc cacctggtca 10380
cgcactgtta agccgctgta tgacgctctg gtggtgcaat gccacaaaga agagtcaatc 10440
gcagacaaca ttttgaatgc ggtcacacgt tagcagcatg attgccacgg atggcaacat 10500
attaacggca tgatattgac ttattgaata aaattgggta aatttgactc aacgatgggt 10560
taattcgctc gttgtggtag tgagatgaaa agaggcggcg cttactaccg attccgccta 10620
gttggtcact tcgacgtatc gtctggaact ccaaccatcg caggcagaga ggtctgcaaa 10680
atgcaatccc gaaacagttc gcaggtaata gttagagcct gcataacggt ttcgggattt 10740
tttatatctg cacaacaggt aagagcattg agtcgataat cgtgaagagt cggcgagcct 10800
ggttagccag tgctctttcc gttgtgctga attaagcgaa taccggaagc agaaccggat 10860
caccaaatgc gtacaggcgt catcgccgcc cagcaacagc acaacccaaa ctgagccgta 10920
gccactgtct gtcctgaatt cattagtaat agttacgctg cggcctttta cacatgacct 10980
tcgtgaaagc gggtggcagg aggtcgcgct aacaacctcc tgccgttttg cccgtgcata 11040
tcggtcacga acaaatctga ttactaaaca cagtagcctg gatttgttct atcagtaatc 11100
gaccttattc ctaattaaat agagcaaatc cccttattgg gggtaagaca tgaagatgcc 11160
agaaaaacat gacctgttgg ccgccattct cgcggcaaag gaacaaggca tcggggcaat 11220
ccttgcgttt gcaatggcgt accttcgcgg cagatataat ggcggtgcgt ttacaaaaac 11280
agtaatcgac gcaacgatgt gcgccattat cgcctagttc attcgtgacc ttctcgactt 11340
cgccggacta agtagcaatc tcgcttatat aacgagcgtg tttatcggct acatcggtac 11400
tgactcgatt ggttcgctta tcaaacgctt cgctgctaaa aaagccggag tagaagatgg 11460
tagaaatcaa taatcaacgt aaggcgttcc tcgatatgct ggcgtggtcg gagggaactg 11520
ataacggacg tcagaaaacc agaaatcatg gttatgacgt cattgtaggc ggagagctat 11580
ttactgatta ctccgatcac cctcgcaaac ttgtcacgct aaacccaaaa ctcaaatcaa 11640
caggctaaga ctggccgtcg ttttacaaca cagaaagagt ttgtagaaac gcaaaaaggc 11700
catccgtcag gggccttctg cttagtttga tgcctggcag ttccctactc tcgccttccg 11760
cttcctcgct cactgactcg ctgcgctcgg tcgttcggct gcggcgagcg gtatcagctc 11820
actcaaaggc ggtaatacgg ttatccacag aatcagggga taacgcagga aagaacatgt 11880
gagcaaaagg ccagcaaaag gccaggaacc gtaaaaaggc cgcgttgctg gcgtttttcc 11940
ataggctccg cccccctgac gagcatcaca aaaatcgacg ctcaagtcag aggtggcgaa 12000
acccgacagg actataaaga taccaggcgt ttccccctgg aagctccctc gtgcgctctc 12060
ctgttccgac cctgccgctt accggatacc tgtccgcctt tctcccttcg ggaagcgtgg 12120
cgctttctca tagctcacgc tgtaggtatc tcagttcggt gtaggtcgtt cgctccaagc 12180
tgggctgtgt gcacgaaccc cccgttcagc ccgaccgctg cgccttatcc ggtaactatc 12240
gtcttgagtc caacccggta agacacgact tatcgccact ggcagcagcc actggtaaca 12300
ggattagcag agcgaggtat gtaggcggtg ctacagagtt cttgaagtgg tgggctaact 12360
acggctacac tagaagaaca gtatttggta tctgcgctct gctgaagcca gttaccttcg 12420
gaaaaagagt tggtagctct tgatccggca aacaaaccac cgctggtagc ggtggttttt 12480
ttgtttgcaa gcagcagatt acgcgcagaa aaaaaggatc tcaagaagat cctttgatct 12540
tttctacggg gtctgacgct cagtggaacg acgcgcgcgt aactcacgtt aagggatttt 12600
ggtcatgagc ttgcgccgtc ccgtcaagtc agcgtaatgc tctgct 12646
<210> 16
<211> 12451
<212> DNA
<213> Artificial Sequence
<220>
<223> CT37
<400> 16
tagaaaaact catcgagcat caaatgaaat tgcaatttat tcatatcagg attatcaata 60
ccatattttt gaaaaagccg tttctgtaat gaaggagaaa actcaccgag gcagttccat 120
aggatggcaa gatcctggta tcggtctgcg attccgactc gtccaacatc aatacaacct 180
attaatttcc cctcgtcaaa aataaggtta tcaagtgaga aatcaccatg agtgacgact 240
gaatccggtg agaatggcaa aagtttatgc atttctttcc agacttgttc aacaggccag 300
ccattacgct cgtcatcaaa atcactcgca tcaaccaaac cgttattcat tcgtgattgc 360
gcctgagcga ggcgaaatac gcgatcgctg ttaaaaggac aattacaaac aggaatcgag 420
tgcaaccggc gcaggaacac tgccagcgca tcaacaatat tttcacctga atcaggatat 480
tcttctaata cctggaacgc tgtttttccg gggatcgcag tggtgagtaa ccatgcatca 540
tcaggagtac ggataaaatg cttgatggtc ggaagtggca taaattccgt cagccagttt 600
agtctgacca tctcatctgt aacatcattg gcaacgctac ctttgccatg tttcagaaac 660
aactctggcg catcgggctt cccatacaag cgatagattg tcgcacctga ttgcccgaca 720
ttatcgcgag cccatttata cccatataaa tcagcatcca tgttggaatt taatcgcggc 780
ctcgacgttt cccgttgaat atggctcata ttcttccttt ttcaatatta ttgaagcatt 840
tatcagggtt attgtctcat gagcggatac atatttgaat gtatttagaa aaataaacaa 900
ataggggtca gtgttacaac caattaacca attctgaaca ttatcgcgag cccatttata 960
cctgaatatg gctcataaca ccccttgttt gcctggcggc agtagcgcgg tggtcccacc 1020
tgaccccatg ccgaactcag aagtgaaacg ccgtagcgcc gatggtagtg tggggactcc 1080
ccatgcgaga gtagggaact gccaggcatc aaataaaacg aaaggctcag tcgaaagact 1140
gggcctttcg cccgggctaa ttagggggtg tcgcccttat tcgactctat agtgaagttc 1200
ctattctcta gaaagtatag gaacttctga agtggggtcg acttaattaa ggctgcgcgc 1260
tcgctcgctc actgaggccg cccgggcaaa gcccgggcgt cgggcgacct ttggtcgccc 1320
ggcctcagtg agcgagcgag cgcgcagaga gggagtggcc aactccatca ctaggggttc 1380
cttgtagtta atgattaacc cgccatgcta cttatctacg tagcaagcta gctagttatt 1440
aatagtaatc aattacgggg tcattagttc atagcccata tatggagttc cgcgttacat 1500
aacttacggt aaatggcccg cctggctgac cgcccaacga cccccgccca ttgacgtcaa 1560
taatgacgta tgttcccata gtaacgccaa tagggacttt ccattgacgt caatgggtgg 1620
agtatttacg gtaaactgcc cacttggcag tacatcaagt gtatcatatg ccaagtacgc 1680
cccctattga cgtcaatgac ggtaaatggc ccgcctggca ttatgcccag tacatgacct 1740
tatgggactt tcctacttgg cagtacatct acgtattagt catcgctatt aacatggtcg 1800
aggtgagccc cacgttctgc ttcactctcc ccatctcccc cccctcccca cccccaattt 1860
tgtatttatt tattttttaa ttattttgtg cagcgatggg ggcggggggg gggggggggc 1920
gcgcgccagg cggggcgggg cggggcgagg ggcggggcgg ggcgaggcgg agaggtgcgg 1980
cggcagccaa tcagagcggc gcgctccgaa agtttccttt tatggcgagg cggcggcggc 2040
ggcggcccta taaaaagcga agcgcgcggc gggcgggagt cgctgcgcgc tgccttcgcc 2100
ccgtgccccg ctccgccgcc gcctcgcgcc gcccgccccg gctctgactg accgcgttac 2160
tcccacaggt gagcgggcgg gagcacggcc cggcttcggg tgcggggctc cgtacggggc 2220
gtggcgcggg gctcgccgtg ccgggcgggg ggtggcggca ggtgggggtg ccgggcgggg 2280
cggggccgcc tcgggccggg gagggctcgg gggaggggcg cggcggcccc cggagcgccg 2340
gcggctgtcg aggcgcggcg agccgcagcc attgcctttt atggtaatcg tgcgagaggg 2400
cgcagggact tcctttgtcc caaatctgtg cggagccgaa atctgggagg cgccgccgca 2460
ccccctctag cgggcgcggg gcgaagcggt gcggcgccgg caggaaggaa atgggcgggg 2520
agggccttcg tgcgtcgccg cgccgccgtc cccttctccc tctccagcct cggggctgtc 2580
cgcgggggga cggctgcctt cgggggggac ggggcagggc ggggttcggc ttctggcgtg 2640
tgaccggcgg ctctagacaa ttgtactaac cttcttctct ttcctctcct gacaggttgg 2700
tgtacactag cggccgccac catggcctcc ctgttctctg gccgcatcct gatccgcaac 2760
aatagcgacc aggacgagct ggatacggag gctgaggtca gtcgcaggct ggagaaccgg 2820
ctggtgctgc tgttctttgg tgctggggct tgtccacagt gccaggcctt cgtgcccatc 2880
ctcaaggact tcttcgtgcg gctcacagat gagttctatg tactgcgggc ggctcagctg 2940
gccctggtgt acgtgtccca ggactccacg gaggagcagc aggacctgtt cctcaaggac 3000
atgccaaaga aatggctttt cctgcccttt gaggatgatc tgaggaggtg atcatctcat 3060
ggatccaaga gatctgcctc gactgtgcct tctagttgcc agccatctgt tgtttgcccc 3120
tcccccgtgc cttccttgac cctggaaggt gccactccca ctgtcctttc ctaataaaat 3180
gaggaaattg catcgcattg tctgagtagg tgtcattcta ttctgggggg tggggtgggg 3240
caggacagca agggggagga ttgggaagac aatagcaggc atgctgggga ctcgaaagga 3300
aaatgaagtg aagttcctat actttctaga gaataggaac ttctatagtg agtcgaataa 3360
gggcgacaca aaatttattc taaatgcata ataaatactg ataacatctt atagtttgta 3420
ttatattttg tattatcgtt gacatgtata attttgatat caaaaactga ttttcccttt 3480
attattttcg agatttattt tcttaattct ctttaacaaa ctagaaatat tgtatataca 3540
aaaaatcata aataatagat gaatagttta attataggtg ttcatcaatc gaaaaagcaa 3600
cgtatcttat ttaaagtgcg ttgctttttt ctcatttata aggttaaata attctcatat 3660
atcaagcaaa gtgacaggcg cccttaaata ttctgacaaa tgctctttcc ctaaactccc 3720
cccataaaaa aacccgccga agcgggtttt tacgttattt gcggattaac gattactcgt 3780
tatcagaacc gcccaggggg cccgagctta ctagctagtt attaatagta atcaattacg 3840
gggtcattag ttcatagccc atatatggag ttccgcgtta cataacttac ggtaaatggc 3900
ccgcctggct gaccgcccaa cgacccccgc ccattgacgt caataatgac gtatgttccc 3960
atagtaacgc caatagggac tttccattga cgtcaatggg tggagtattt acggtaaact 4020
gcccacttgg cagtacatca agtgtatcat atgccaagta cgccccctat tgacgtcaat 4080
gacggtaaat ggcccgcctg gcattatgcc cagtacatga ccttatggga ctttcctact 4140
tggcagtaca tctacgtatt agtcatcgct attaacatgg tcgaggtgag ccccacgttc 4200
tgcttcactc tccccatctc ccccccctcc ccacccccaa ttttgtattt atttattttt 4260
taattatttt gtgcagcgat gggggcgggg gggggggggg ggcgcgcgcc aggcggggcg 4320
gggcggggcg aggggcgggg cggggcgagg cggagaggtg cggcggcagc caatcagagc 4380
ggcgcgctcc gaaagtttcc ttttatggcg aggcggcggc ggcggcggcc ctataaaaag 4440
cgaagcgcgc ggcgggcggg gagtcgctgc gcgctgcctt cgccccgtgc cccgctccgc 4500
cgccgcctcg cgccgcccgc cccggctctg actgaccgcg ttactcccac aggtgagcgg 4560
gcgggatgag cacggcccgg cttcgggtgc ggggctccgt acggggcgtg gcgcggggct 4620
cgccgtgccg ggcggggggt ggcggcaggt gggggtgccg ggcggggcgg ggccgcctcg 4680
ggccggggag ggctcggggg aggggcgcgg cggcccccgg agcgccggcg gctgtcgagg 4740
cgcggcgagc cgcagccatt gccttttatg gtaatcgtgc gagagggcgc agggacttcc 4800
tttgtcccaa atctgtgcgg agccgaaatc tgggaggcgc cgccgcaccc cctctagcgg 4860
gcgcggggcg aagcggtgcg gcgccggcag gaaggaaatg ggcggggagg gccttcgtgc 4920
gtcgccgcgc cgccgtcccc ttctccctct ccagcctcgg ggctgtccgc ggggggacgg 4980
ctgccttcgg gggggacggg gcagggcggg gttcggcttc tggcgtgtga ccggcggctc 5040
tagacaattg tactaacctt cttctctttc ctctcctgac aggttggtgt acactagcgg 5100
ccgccaccat ggcctccctg ttctctggcc gcatcctgat ccgcaacaat agcgaccagg 5160
acgagctgga tacggaggct gaggtcagtc gcaggctgga gaaccggctg gtgctgctgt 5220
tctttggtgc tggggcttgt ccacagtgcc aggccttcgt gcccatcctc aaggacttct 5280
tcgtgcggct cacagatgag ttctatgtac tgcgggcggc tcagctggcc ctggtgtacg 5340
tgtcccagga ctccacggag gagcagcagg acctgttcct caaggacatg ccaaagaaat 5400
ggcttttcct gccctttgag gatgatctga ggaggtgatc atctcatgga tccaagagat 5460
ctgcctcgac tgtgccttct agttgccagc catctgttgt ttgcccctcc cccgtgcctt 5520
ccttgaccct ggaaggtgcc actcccactg tcctttccta ataaaatgag gaaattgcat 5580
cgcattgtct gagtaggtgt cattctattc tggggggtgg ggtggggcag gacagcaagg 5640
gggaggattg ggaagacaat agcaggcatg ctggggactc gagttctacg tagataagta 5700
gcatggcggg ttaatcatta actacaagga acccctagtg atggagttgg ccactccctc 5760
tctgcgcgct cgctcgctca ctgaggccgg gcgaccaaag gtcgcccgac gcccgggctt 5820
tgcccgggcg gcctcagtga gcgagcgagc gcgcagcctt aattaaccta aggaaaatga 5880
agtgaagttc ctatactttc tagagaatag gaacttctat agtgagtcga ataagggcga 5940
cacaaaattt attctaaatg cataataaat actgataaca tcttatagtt tgtattatat 6000
tttgtattat cgttgacatg tataattttg atatcaaaaa ctgattttcc ctttattatt 6060
ttcgagattt attttcttaa ttctctttaa caaactagaa atattgtata tacaaaaaat 6120
cataaataat agatgaatag tttaattata ggtgttcatc aatcgaaaaa gcaacgtatc 6180
ttatttaaag tgcgttgctt ttttctcatt tataaggtta aataattctc atatatcaag 6240
caaagtgaca ggcgccctta aatattctga caaatgctct ttccctaaac tccccccata 6300
aaaaaacccg ccgaagcggg tttttacgtt atttgcggat taacgattac tcgttatcag 6360
aaccgcccag ggggcccgag cttaaccttt ttatttgggg gagagggaag tcatgaaaaa 6420
actaaccttt gaaattcgat ctccagcaca tcagcaaaac gctattcacg cagtacagca 6480
aatccttcca gacccaacca aaccaatcgt agtaaccatt caggaacgca accgcagctt 6540
agaccaaaac aggaagctat gggcctgctt aggtgacgtc tctcgtcagg ttgaatggca 6600
tggtcgctgg ctggatgcag aaagctggaa gtgtgtgttt accgcagcat taaagcagca 6660
ggatgttgtt cctaaccttg ccgggaatgg ctttgtggta ataggccagt caaccagcag 6720
gatgcgtgta ggcgaatttg cggagctatt agagcttata caggcattcg gtacagagcg 6780
tggcgttaag tggtcagacg aagcgagact ggctctggag tggaaagcga gatggggaga 6840
cagggctgca tgataaatgt cgttagtttc tccggtggca ggacgtcagc atatttgctc 6900
tggctaatgg agcaaaagcg acgggcaggt aaagacgtgc attacgtttt catggataca 6960
ggttgtgaac atccaatgac atatcggttt gtcagggaag ttgtgaagtt ctgggatata 7020
ccgctcaccg tattgcaggt tgatatcaac ccggagcttg gacagccaaa tggttatacg 7080
gtatgggaac caaaggatat tcagacgcga atgcctgttc tgaagccatt tatcgatatg 7140
gtaaagaaat atggcactcc atacgtcggc ggcgcgttct gcactgacag attaaaactc 7200
gttcccttca ccaaatactg tgatgaccat ttcgggcgag ggaattacac cacgtggatt 7260
ggcatcagag ctgatgaacc gaagcggcta aagccaaagc ctggaatcag atatcttgct 7320
gaactgtcag actttgagaa ggaagatatc ctcgcatggt ggaagcaaca accattcgat 7380
ttgcaaatac cggaacatct cggtaactgc atattctgca ttaaaaaatc aacgcaaaaa 7440
atcggacttg cctgcaaaga tgaggaggga ttgcagcgtg tttttaatga ggtcatcacg 7500
ggatcccatg tgcgtgacgg acatcgggaa acgccaaagg agattatgta ccgaggaaga 7560
atgtcgctgg acggtatcgc gaaaatgtat tcagaaaatg attatcaagc cctgtatcag 7620
gacatggtac gagctaaaag attcgatacc ggctcttgtt ctgagtcatg cgaaatattt 7680
ggagggcagc ttgatttcga cttcgggagg gaagctgcat gatgcgatgt tatcggtgcg 7740
gtgaatgcaa agaagataac cgcttccgac caaatcaacc ttactggaat cgatggtgtc 7800
tccggtgtga aagaacacca acaggggtgt taccactacc gcaggaaaag gaggacgtgt 7860
ggcgagacag cgacgaagta tcaccgacat aatctgcgaa aactgcaaat accttccaac 7920
gaaacgcacc agaaataaac ccaagccaat cccaaaagaa tctgacgtaa aaaccttcaa 7980
ctacacggct cacctgtggg atatccggtg gctaagacgt cgtgcgagga aaacaaggtg 8040
attgaccaaa atcgaagtta cgaacaagaa agcgtcgagc gagctttaac gtgcgctaac 8100
tgcggtcaga agctgcatgt gctggaagtt cacgtgtgtg agcactgctg cgcagaactg 8160
atgagcgatc cgaatagctc gatgcacgag gaagaagatg atggctaaac cagcgcgaag 8220
acgatgtaaa aacgatgaat gccgggaatg gtttcaccct gcattcgcta atcagtggtg 8280
gtgctctcca gagtgtggaa ccaagatagc actcgaacga cgaagtaaag aacgcgaaaa 8340
agcggaaaaa gcagcagaga agaaacgacg acgagaggag cagaaacaga aagataaact 8400
taagattcga aaactcgcct taaagccccg cagttactgg attaaacaag cccaacaagc 8460
cgtaaacgcc ttcatcagag aaagagaccg cgacttacca tgtatctcgt gcggaacgct 8520
cacgtctgct cagtgggatg ccggacatta ccggacaact gctgcggcac ctcaactccg 8580
atttaatgaa cgcaatattc acaagcaatg cgtggtgtgc aaccagcaca aaagcggaaa 8640
tctcgttccg tatcgcgtcg aactgattag ccgcatcggg caggaagcag tagacgaaat 8700
cgaatcaaac cataaccgcc atcgctggac tatcgaagag tgcaaggcga tcaaggcaga 8760
gtaccaacag aaactcaaag acctgcgaaa tagcagaagt gaggccgcat gacgttctca 8820
gtaaaaacca ttccagacat gctcgttgaa acatacggaa atcagacaga agtagcacgc 8880
agactgaaat gtagtcgcgg tacggtcaga aaatacgttg atgataaaga cgggaaaatg 8940
cacgccatcg tcaacgacgt tctcatggtt catcgcggat ggagtgaaag agatgcgcta 9000
ttacgaaaaa attgatggca gcaaataccg aaatatttgg gtagttggcg atctgcacgg 9060
atgctacacg aacctgatga acaaactgga tacgattgga ttcgacaaca aaaaagacct 9120
gcttatctcg gtgggcgatt tggttgatcg tggtgcagag aacgttgaat gcctggaatt 9180
aatcacattc ccctggttca gagctgtacg tggaaaccat gagcaaatga tgattgatgg 9240
cttatcagag cgtggaaacg ttaatcactg gctgcttaat ggcggtggct ggttctttaa 9300
tctcgattac gacaaagaaa ttctggctaa agctcttgcc cataaagcag atgaacttcc 9360
gttaatcatc gaactggtga gcaaagataa aaaatatgtt atctgccacg ccgattatcc 9420
ctttgacgaa tacgagtttg gaaagccagt tgatcatcag caggtaatct ggaaccgcga 9480
acgaatcagc aactcacaaa acgggatcgt gaaagaaatc aaaggcgcgg acacgttcat 9540
ctttggtcat acgccagcag tgaaaccact caagtttgcc aaccaaatgt atatcgatac 9600
cggcgcagtg ttctgcggaa acctaacatt gattcaggta cagggagaag gcgcatgaga 9660
ctcgaaagcg tagctaaatt tcattcgcca aaaagcccga tgatgagcga ctcaccacgg 9720
gccacggctt ctgactctct ttccggtact gatgtgatgg ctgctatggg gatggcgcaa 9780
tcacaagccg gattcggtat ggctgcattc tgcggtaagc acgaactcag ccagaacgac 9840
aaacaaaagg ctatcaacta tctgatgcaa tttgcacaca aggtatcggg gaaataccgt 9900
ggtgtggcaa agcttgaagg aaatactaag gcaaaggtac tgcaagtgct cgcaacattc 9960
gcttatgcgg attattgccg tagtgccgcg acgccggggg caagatgcag agattgccat 10020
ggtacaggcc gtgcggttga tattgccaaa acagagctgt gggggagagt tgtcgagaaa 10080
gagtgcggaa gatgcaaagg cgtcggctat tcaaggatgc cagcaagcgc agcatatcgc 10140
gctgtgacga tgctaatccc aaaccttacc caacccacct ggtcacgcac tgttaagccg 10200
ctgtatgacg ctctggtggt gcaatgccac aaagaagagt caatcgcaga caacattttg 10260
aatgcggtca cacgttagca gcatgattgc cacggatggc aacatattaa cggcatgata 10320
ttgacttatt gaataaaatt gggtaaattt gactcaacga tgggttaatt cgctcgttgt 10380
ggtagtgaga tgaaaagagg cggcgcttac taccgattcc gcctagttgg tcacttcgac 10440
gtatcgtctg gaactccaac catcgcaggc agagaggtct gcaaaatgca atcccgaaac 10500
agttcgcagg taatagttag agcctgcata acggtttcgg gattttttat atctgcacaa 10560
caggtaagag cattgagtcg ataatcgtga agagtcggcg agcctggtta gccagtgctc 10620
tttccgttgt gctgaattaa gcgaataccg gaagcagaac cggatcacca aatgcgtaca 10680
ggcgtcatcg ccgcccagca acagcacaac ccaaactgag ccgtagccac tgtctgtcct 10740
gaattcatta gtaatagtta cgctgcggcc ttttacacat gaccttcgtg aaagcgggtg 10800
gcaggaggtc gcgctaacaa cctcctgccg ttttgcccgt gcatatcggt cacgaacaaa 10860
tctgattact aaacacagta gcctggattt gttctatcag taatcgacct tattcctaat 10920
taaatagagc aaatcccctt attgggggta agacatgaag atgccagaaa aacatgacct 10980
gttggccgcc attctcgcgg caaaggaaca aggcatcggg gcaatccttg cgtttgcaat 11040
ggcgtacctt cgcggcagat ataatggcgg tgcgtttaca aaaacagtaa tcgacgcaac 11100
gatgtgcgcc attatcgcct agttcattcg tgaccttctc gacttcgccg gactaagtag 11160
caatctcgct tatataacga gcgtgtttat cggctacatc ggtactgact cgattggttc 11220
gcttatcaaa cgcttcgctg ctaaaaaagc cggagtagaa gatggtagaa atcaataatc 11280
aacgtaaggc gttcctcgat atgctggcgt ggtcggaggg aactgataac ggacgtcaga 11340
aaaccagaaa tcatggttat gacgtcattg taggcggaga gctatttact gattactccg 11400
atcaccctcg caaacttgtc acgctaaacc caaaactcaa atcaacaggc taagactggc 11460
cgtcgtttta caacacagaa agagtttgta gaaacgcaaa aaggccatcc gtcaggggcc 11520
ttctgcttag tttgatgcct ggcagttccc tactctcgcc ttccgcttcc tcgctcactg 11580
actcgctgcg ctcggtcgtt cggctgcggc gagcggtatc agctcactca aaggcggtaa 11640
tacggttatc cacagaatca ggggataacg caggaaagaa catgtgagca aaaggccagc 11700
aaaaggccag gaaccgtaaa aaggccgcgt tgctggcgtt tttccatagg ctccgccccc 11760
ctgacgagca tcacaaaaat cgacgctcaa gtcagaggtg gcgaaacccg acaggactat 11820
aaagatacca ggcgtttccc cctggaagct ccctcgtgcg ctctcctgtt ccgaccctgc 11880
cgcttaccgg atacctgtcc gcctttctcc cttcgggaag cgtggcgctt tctcatagct 11940
cacgctgtag gtatctcagt tcggtgtagg tcgttcgctc caagctgggc tgtgtgcacg 12000
aaccccccgt tcagcccgac cgctgcgcct tatccggtaa ctatcgtctt gagtccaacc 12060
cggtaagaca cgacttatcg ccactggcag cagccactgg taacaggatt agcagagcga 12120
ggtatgtagg cggtgctaca gagttcttga agtggtgggc taactacggc tacactagaa 12180
gaacagtatt tggtatctgc gctctgctga agccagttac cttcggaaaa agagttggta 12240
gctcttgatc cggcaaacaa accaccgctg gtagcggtgg tttttttgtt tgcaagcagc 12300
agattacgcg cagaaaaaaa ggatctcaag aagatccttt gatcttttct acggggtctg 12360
acgctcagtg gaacgacgcg cgcgtaactc acgttaaggg attttggtca tgagcttgcg 12420
ccgtcccgtc aagtcagcgt aatgctctgc t 12451
Claims (9)
- - RdCVF를 코딩하는 제1 핵산을 포함하는 제1 발현 카세트 및
- RdCVFL을 코딩하는 제2 핵산을 포함하는 제2 발현 카세트를 포함하고,
상기 제1 및 제2 발현 카세트는 200개 미만의 연속적으로 동일한 뉴클레오티드(contiguous identical nucleotides)를 디스플레이하는 아데노-관련 벡터(adeno-associated vector, AAV). - 제1항에 있어서, 상기 아데노-관련 벡터(AAV)는 혈청형 AAV2/8인, 아데노-관련 벡터.
- 제1항 또는 제2항 중 어느 한 항에 있어서, 상기 RdCVF를 코딩하는 제1 핵산은 편재성 프로모터, 바람직하게는 CMV/CBA 프로모터의 조절 하에 있는, 아데노-관련 벡터.
- 제1항 내지 제3항 중 어느 한 항에 있어서, 상기 RdCVFL을 코딩하는 제2 핵산은 간체-옵신 프로모터의 조절 하에 있는, 아데노-관련 벡터.
- 제1항 내지 제4항 중 어느 한 항에 있어서, 상기 아데노-관련 벡터는 서열번호 6, 서열번호 7, 서열번호 8 및 서열번호 9로 이루어진 그룹, 바람직하게는 서열번호 6으로 표시되는 핵산 서열을 갖는, 아데노-관련 벡터.
- 제1항 내지 제4항 중 어느 한 항에 있어서, 상기 아데노-관련 벡터는 서열번호 10의 스터퍼 서열(stuffer sequence)을 추가로 포함하는, 아데노-관련 벡터.
- 제1항 내지 제6항 중 어느 한 항에 있어서, 상기 아데노-관련 벡터는 망막 신경퇴행성 장애의 치료 방법에 사용되는, 아데노-관련 벡터.
- - RdCVF를 코딩하는 제1 핵산을 포함하는 제1 발현 카세트 및
- RdCVFL을 코딩하는 제2 핵산을 포함하는 제2 발현 카세트를 포함하고,
상기 제1 및 제2 발현 카세트는 200개 미만의 연속적으로 동일한 뉴클레오티드를 디스플레이하는 아데노-관련 벡터의 치료적 유효량을 망막 퇴행성 질환 환자에게 투여하는 것으로 이루어진 단계를 포함하는, 망막 퇴행성 질환 환자의 치료 방법. - 서열번호 10으로 표시되는 서열을 갖는 핵산을 포함하되, 상기 서열번호 10으로 표시되는 서열을 갖는 핵산은 발현 카세트에는 존재하지 않는 아데노-관련 벡터.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17306915 | 2017-12-22 | ||
EP17306915.4 | 2017-12-22 | ||
PCT/EP2018/086744 WO2019122403A1 (en) | 2017-12-22 | 2018-12-21 | Constructs comprising neuronal viability factors and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20200107990A true KR20200107990A (ko) | 2020-09-16 |
Family
ID=60971954
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020207021370A KR20200107990A (ko) | 2017-12-22 | 2018-12-21 | 신경 생존 인자를 포함하는 컨스트럭트 및 이의 용도 |
Country Status (13)
Country | Link |
---|---|
US (1) | US20200318138A1 (ko) |
EP (1) | EP3728610B1 (ko) |
JP (1) | JP7231647B2 (ko) |
KR (1) | KR20200107990A (ko) |
CN (1) | CN111742052B (ko) |
AU (1) | AU2018387826B2 (ko) |
BR (1) | BR112020012471A2 (ko) |
CA (1) | CA3086292A1 (ko) |
DK (1) | DK3728610T5 (ko) |
ES (1) | ES2949484T3 (ko) |
IL (1) | IL275529A (ko) |
SG (1) | SG11202006796RA (ko) |
WO (1) | WO2019122403A1 (ko) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2027889A1 (en) * | 2007-06-05 | 2009-02-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | New neuronal viability factor and use thereof |
KR20230142576A (ko) * | 2021-02-05 | 2023-10-11 | 메이즈 테라퓨틱스, 인코퍼레이티드 | 스터퍼 폴리뉴클레오티드 서열을 포함하는 벡터 |
WO2022223644A2 (en) * | 2021-04-20 | 2022-10-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions and methods for treating retinal degenerative disorders |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2027889A1 (en) | 2007-06-05 | 2009-02-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | New neuronal viability factor and use thereof |
WO2012158757A1 (en) | 2011-05-16 | 2012-11-22 | The Trustees Of The University Of Pennsylvania | Proviral plasmids for production of recombinant adeno-associated virus |
CA2853379C (en) * | 2011-10-27 | 2020-11-24 | Wellstat Ophthalmics Corporation | Vectors encoding rod-derived cone viability factor |
JP6684343B2 (ja) * | 2015-05-21 | 2020-04-22 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | ニューロン生存因子の相乗組み合わせ及びその使用 |
US10857240B2 (en) * | 2016-01-05 | 2020-12-08 | The Trustees Of The University Of Pennsylvania | Methods and compositions for treatment of ocular disorders and blinding diseases |
-
2018
- 2018-12-21 CN CN201880089629.4A patent/CN111742052B/zh active Active
- 2018-12-21 EP EP18826078.0A patent/EP3728610B1/en active Active
- 2018-12-21 CA CA3086292A patent/CA3086292A1/en active Pending
- 2018-12-21 BR BR112020012471-0A patent/BR112020012471A2/pt unknown
- 2018-12-21 AU AU2018387826A patent/AU2018387826B2/en active Active
- 2018-12-21 SG SG11202006796RA patent/SG11202006796RA/en unknown
- 2018-12-21 JP JP2020554934A patent/JP7231647B2/ja active Active
- 2018-12-21 US US16/956,894 patent/US20200318138A1/en not_active Abandoned
- 2018-12-21 ES ES18826078T patent/ES2949484T3/es active Active
- 2018-12-21 WO PCT/EP2018/086744 patent/WO2019122403A1/en unknown
- 2018-12-21 KR KR1020207021370A patent/KR20200107990A/ko not_active Application Discontinuation
- 2018-12-21 DK DK18826078.0T patent/DK3728610T5/da active
-
2020
- 2020-06-21 IL IL275529A patent/IL275529A/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2021508493A (ja) | 2021-03-11 |
DK3728610T5 (da) | 2024-08-26 |
EP3728610B1 (en) | 2023-05-31 |
SG11202006796RA (en) | 2020-08-28 |
CN111742052B (zh) | 2024-10-11 |
AU2018387826B2 (en) | 2024-06-13 |
EP3728610A1 (en) | 2020-10-28 |
AU2018387826A1 (en) | 2020-08-06 |
BR112020012471A2 (pt) | 2020-11-24 |
ES2949484T3 (es) | 2023-09-28 |
DK3728610T3 (da) | 2023-08-07 |
WO2019122403A1 (en) | 2019-06-27 |
IL275529A (en) | 2020-08-31 |
US20200318138A1 (en) | 2020-10-08 |
CA3086292A1 (en) | 2019-06-27 |
JP7231647B2 (ja) | 2023-03-01 |
CN111742052A (zh) | 2020-10-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2020260485B2 (en) | Gene therapies for lysosomal disorders | |
AU2020260476B2 (en) | Gene therapies for lysosomal disorders | |
KR102693318B1 (ko) | 리소좀 장애를 위한 유전자 요법 | |
KR102111244B1 (ko) | 이종 유전자의 발현을 위한 강력한 짧은 프로모터 | |
KR20220006527A (ko) | 리소좀 장애에 대한 유전자 요법 | |
KR20210150486A (ko) | 리소좀 장애에 대한 유전자 요법 | |
KR20230066360A (ko) | 신경퇴행성 장애를 위한 유전자 요법 | |
KR20200107990A (ko) | 신경 생존 인자를 포함하는 컨스트럭트 및 이의 용도 | |
CN114502575A (zh) | 用于arsa基因转移的腺相关病毒组合物和其使用方法 | |
CN116685329A (zh) | 核酸构建体及其用于治疗脊髓性肌肉萎缩症的用途 | |
KR102545070B1 (ko) | 안구 장애에 대한 유전자 치료 | |
KR20230043123A (ko) | Glut1 발현을 위한 아데노-연관 바이러스 벡터 및 이의 사용 | |
KR20070114761A (ko) | Sivpedf 벡터를 사용한 안조직 세포에 있어서의아포토시스 변성을 동반하는 질환의 치료제 | |
CN101160139A (zh) | 含有pedf以及fgf2的伴随眼组织细胞凋亡变性的疾患的治疗药物 | |
KR20230051529A (ko) | 리소좀 장애에 대한 유전자 요법 | |
KR20210150487A (ko) | 리소좀 장애를 위한 유전자 요법 | |
CN117836420A (zh) | 重组tert编码病毒基因组和运载体 | |
KR20220128632A (ko) | 개선된 aav-abcd1 구축물 및 부신백질이영양증 (ald) 및/또는 부신척수신경병증 (amn)의 치료 또는 예방을 위한 용도 | |
WO2023150743A2 (en) | Codon-optimized smad7 gene therapy to treat and prevent muscle wasting and to enhance muscle mass | |
CN116669774A (zh) | 用于治疗法布里病的组合物和方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal |